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Peptide synthesis and modification is a versatile chemical biology strategy to 
construct probes and sensors of a variety of types of biological activity, including 
protein/protein interactions, protein localization, and proteolysis. In my thesis work, 
I have made probes for three distinct biological applications. To do so, I have used 
a combination of solid phase peptide synthesis (SPPS), native chemical ligation 
(NCL), protein expression, and S-alkylation to construct probes with desired 
functional groups, while minimizing the perturbation to the native structure. In the 
first project, I constructed photo-crosslinking probes to study the difference in 
protein-protein interactions of N-terminal acetylated (N-ac) histone H4 peptide 
versus non-acetylated histone H4 peptide. One protein was identified by Western 
blot with binding preference to N-Ace histone H4 peptide. In the second separate 
project, I constructed probes to study the toxicity mechanism of proline/arginine 
dipeptide PRx from amyotrophic lateral sclerosis (ALS) associated gene C9ORF72. 
The preliminary result suggested the PRx peptide toxicity on proteasome depends 
on the length of the (PR)x peptide. In the third project, I synthesized fluorescence 
sensors to study the positional effects of thioamide on the proteolysis process of 
chymotrypsin. From hydrolysis studies, my coworkers and I determined that 
thioamide incorporation at the P1 or P2 positions can greatly inhibit chymotrypsin 
proteolysis. 
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Chapter 1  
Development of Protein Binding Probes 
 
Introduction 
 
Peptide synthesis and protein modification are powerful synthetic strategies that 
combine the flexibility of organic synthesis and the convenience of recombinant 
protein expression. By using a combination of synthetic approaches, functional 
groups can be added to the peptides or proteins of interest, such as fluorophores, 
unnatural amino acids, photo-crosslinkers, and purification tags. Similarly, 
synthetic approaches can be used to modify the backbone of the peptide. Modified 
peptides have wide applications in drug design, live imaging, and other biological 
studies. For example, Nafarelin® is an analog of the naturally occurring 
gonadotropin-releasing hormone (GnRH) with modification at position 6 (shown in 
red) in Figure 1A.1 This modification significantly extends the half-life from 2-4 
minutes2 to 2.6-4 hours.1 Another example from Nguyen and coworkers3 showed 
a caged TEV (Tobacco Etch Virus) protease can be activated by release of the 
caging group under light irradiation, allowing manipulation of protease activity by 
light, as shown in Figure 1B. 
 
 
 
Figure 1. Examples of Modified Peptide and Proteins. (A): a GnRH analog 
Nafarelin, marketed as Synarel® by Pfizer.1 (B): The TEV protease is inactivated 
with a caged cysteine.3 
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I hope to use peptide synthesis and modification methods to construct probes 
to solve biological questions. Based on the probes applications, this study is 
divided into projects 1 and 2. Project 1 involves synthesis of photo-crosslinking 
probes and then studies the functions of histone H4 N-terminal acetylation (N-ac). 
Project 2 involves synthesis of a photo-crosslinking probe and a fluorescence 
probe, followed by study on the toxicity mechanism of proline-arginine tandem 
repeat peptides PRx on amyotrophic lateral sclerosis (ALS). Since project 1 and 2 
uses similar methods including solid phase peptide synthesis (SPPS), native 
chemical ligation (NCL), S-alkylation and maleimide labeling, the methods will be 
discussed in one section.  
 
Project 1: Interactions of N-Terminally Acetylated Histones 
 
Importance and Significance Although histone N-terminal acetylation (N-ac) 
was discovered in 1964, the functions of this modification have not been fully 
characterized.4 Recently, Marmorstein and co-workers5 characterized the 
molecular basis of an N-terminal acetyltransferase NatD, which only acetylates 
histone H4 and H2A9. Initial evidence suggests that histone N-ac can alter histone 
in protein bindings, but the potential binding partner(s) was unidentified.5 
Identifying the binding partner(s) can help reveals the functions and mechanism of 
gene regulation.  
Purpose and Hypothesis The purpose of project 1 is to identify the binding 
partner(s) of N-terminally acetylated histones. The Marmorstein group 
hypothesized N-ac of histone H4 could change the binding affinity to its binding 
partner(s) by N-ac, to trigger downstream activities. Therefore, there should be a 
difference in protein binding between non-acetylated histone H4 versus N-ac 
histone H4. It was anticipated that at least one protein target could be identified 
from the photo-crosslinking experiment, possibly a transcription factor or an 
enzyme that deacetylates the N-ac histone. 
Experimental Design To find the putative unknown binding partner(s) 
regulated by histone H4 N-ac, a photo-crosslinking experiment to crosslink histone 
H4 with proteins in the cell lysates was proposed. By comparing the binding 
partner(s) between non-acetylated with N-ac histone H4, protein(s) that shows 
binding preferences towards one type of histone H4 could be identified. The photo-
crosslinking experiment requires a model that mimics the native structure of 
histone H4. The Petersson laboratory devised a peptide probe consists of the first 
22 N-terminal residues of the human histone H4 protein.6 Only the first 22 residues 
were chosen to represent the histone H4 protein because the full length of histone 
H4 protein is over 100 amino acids long, and synthesis of full-length protein is far 
beyond the capacity of SPPS without the aid of ligation methods. To functionalize 
the peptide probe, a photo-lysine residue and a biotin tag were incorporated into 
the sequence. The photo-lysine is a diazirine photo-crosslinker, developed by 
Yang and co-workers.7 In photo-lysine, the diazirine group is embedded in the 
lysine sidechain, having close structural proximity to the native lysine. The 
Petersson laboratory previously synthesized histone H4 peptide with 
benzophenone photo-crosslinker, then a photo-crosslinking experiment was 
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performed by the Marmorstein group. Due to non-specific binding, no useful data 
could be extrapolated (Marmorstein laboratory, University of Pennsylvania, PA, 
USA, unpublished work, 2016). Compared to the benzophenone, the photo-lysine 
can replace the natural lysine residue with minimal perturbation to the native 
peptide, and hence generate more biologically relevant data. The diazirine is also 
more reactive than benzophenone and the binding study requires a shorter UV 
irradiation time. The reduction of time can also reduce non-specific binding 
between the probe and the cell lysate. Therefore, the photo-lysine was chosen as 
the photo crosslinker in this study. The biotin tag was introduced at the C-terminal 
end of the peptide probe to pair with the photo-lysine for pull down experiments. 
My task in this study was to synthesize the probe, and the photo-crosslinking 
experiment was performed by the Marmorstein laboratory.  
Background in Histones N-Terminal Acetylation In eukaryotic cells, histones 
provide the scaffolds for wrapping and compacting DNA and to form the structure 
of nucleosomes. Histones play critical roles in gene expression and are highly 
regulated by amino acid sidechain post-translational modifications (PTMs), which 
have been studied extensively in the past few decades. Different PTMs patterns 
can trigger distinct downstream effects.8 Therefore, the function of a specific PTMs 
is only meaningful in the context of a peptide or protein. A particularly elegant 
approach to study the function of PTMs patterns is to use synthetic peptides with 
defined amino acid sidechain modifications. For example, Muir and co-workers9 
synthesized histone proteins H2B with ubiquitylated lysine 120 and then evaluated 
the effect on protein recruitment and gene transcription. In many cases, PTMs in 
this histone protein resulted in the recruitment of target proteins for gene regulation. 
 
  
Figure 2. Space-filled PHD12 Structure, Highlighting the H3K14ac Peptide (yellow) 
Bound Across the Unified Structure of PHD1 (green) and PHD2 (blue).15 
Source: Adapted with permission from Zeng, L.; Zhang, Q.; Li, S.; Plotnikov, A. N.; Walsh, 
M. J.; Zhou, M. Mechanism and Regulation of Acetylated Histone Binding by the Tandem 
PHD Finger of DPF3b. Nature 2010, 466 (7303), 258–262. Copyright 2017 Nature 
Publishing Group. 
 
The function of histone sidechain acetylation was characterized. For example, 
the H3K14ac modification can change the histone binding to PHD finger motif 
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(Figure 2). Compared to sidechain acetylation, the effect of protein N-ac has not 
been fully characterized. In N-ac, an acetyl group from acetyl-coenzyme A (Ac-
CoA) is transferred to the α-amino group on the first residue of the protein substrate. 
N-acetylation occurs on about 80% of human proteins, either post- or co-
translationally.10 The functions of N-ac are related to protein stability, translocation, 
and protein binding.11,12 Shemorry and coworkers reported that N-ac is one of the 
many factors affecting the ubiquitination pathway.9 Depending on other conditions, 
N-ac can either stabilize the protein or act as a degradation signal.13,14 
There is some preliminary evidence showing histone N-ac can change its 
protein binding partners. Marmorstein and co-workers5 characterized the 
molecular basis of an N-terminal acetyltransferase NatD, which only acetylates 
histone H4 and H2A9. The role of NatD in gene regulation is not fully understood, 
but initial evidence suggests that histone N-ac may regulate the binding of PHD 
finger proteins. The PHD finger is a motif often related to chromatin-mediated gene 
regulation. Another study by Zeng and co-workers15 showed that the PHD finger 
can selectively bind to histones H3 and H4, where the interaction of the PHD 
fingers with H3 is promoted by acetylation at lysine 14, but inhibited by sidechain 
methylation at lysine 4. The differential binding of the PHD fingers alters the gene 
transcription of mouse DPF3b downstream genes Pitx2 and Jmjd1c. 
 
Project 2: Binding Study of (PR)x Peptide to Proteasome  
 
Importance and Significance Amyotrophic lateral sclerosis (ALS, or Lou 
Gehrig's disease) is a progressive, fatal neurodegenerative disease characterized 
by the loss of motor neurons in the brain and spinal cord.16 The prevalence of ALS 
is about 5 cases per 100,000 people and death occurs typically 3–5 years after 
diagnosis. Riluzole17 and Edaravone18 are the only ALS medicaitons approved by 
FDA. The mechanism of ALS is not fully understood, mutations of several genes 
can lead to the development of ALS.19 The microsatellite expansion in C9ORF72 
gene was found to be the most important cause of ALS, which accounts for 
approximately 34.2% of ALS cases.20,21 Undestanding of the mechnism of the 
C9ORF72 gene can provide thoerical background for ALS treatments 
development.  
Purpose and Hypothesis The C9ORF72 gene is transcribed via a repeat-
associated non-AUG (RAN) translation mechanism, where translation can occur 
in both sense and anti-sense transcripts. The translation products of C9ORF72 are 
five different poly-dipeptides: glycine-alanine (GA), glycine-arginine (GR), proline-
arginine (PR) proline-alanine (PA), and glycine-proline (GP). The length of the 
peptides varies among patients, so PRx is used to represent peptides without 
defined length. 
There are two theories about the mechanism of the disease. The RNA toxicity 
theory suggests the disease is the result of RNA toxicity from C9ORF72 
transcription.22 In contrast, the peptide toxicity theory suggests that cell death is 
caused by the translation products of C9ORF72.23 Shi and co-workers24 reported 
that the toxicity of the PRx peptide comes from plugging the nuclear pore, and 
prehibiting communication between the nucleus and cytoplasm. In their study, the 
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stimulated emission depletion (STED) microscopy image shows co-localization of 
the nucleoporin gp210 and the PR20 peptide indicates the PR20 peptide is binding 
to the nuclear pore, as shown in Figure 3. 
 
 
Figure 3. Merged Confocal Microscopic Image of Fluorescein Isothiocynate 
Labeled PR20 Peptide (red) and STED Image of Nucleoporin gp210 (green).25  
 
Source: Adapted with permission form Taylor, J. P. A PR plug for the nuclear pore in 
amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. 2017, 114 (7), 201621085. Copyright 
2017 PNAS. 
 
A separate study by Kalb and co-workers26 reported that the PRx peptide binds 
to the proteasome to inhibit degradation of ubiquitinated substrates, which leads 
to cytotoxicity. These results do not necessarily conflict with each other; it is 
possible that the PRx peptide can bind to several targets in cells. This is likely, 
given its very simple sequence.  
The Kalb group hypothesized that the PRx peptide can bind to certain subunit(s) 
of the proteasome, possibly by plugging the proteasome entrance site and 
resulting in cytotoxicity. This hypothesis can be confirmed by identifing the binding 
pattern of PR20 to the proteasome using photo-crosslinking probes.The Kalb group 
also expect that the PRx peptide can colocalize with the proteasome in the cell for 
the binding event to occur. The second hypothesis can be confirmed by observing 
the colocation of  a fluorocence PR20 peptide with protesome in cell under a 
confocal microscope. My taks in this project was to develop the chemical probes 
needed for the in vitro experiments. All in vitro experiments was performed by the 
Kalb group. 
Experimental Design To confirm the hypothesis that the PRx peptide can bind 
to certain subunit(s) of the proteasome, a photo-crosslinker probe can be used to 
identify the binding partners(s) of PR20 peptide. Similar to project 1, a photo-
crosslinking probe with a photo-crosslinker and a biotin tag was incorporated into 
the PR20 peptide. Since it is difficult to perform the PR20 peptide sidechain 
modification, the photo-corsslinker and biotin tag was added to the terminal of the 
sequence. In the fluorocence PR20 peptide design,  a fluorophore was attached to 
a PR20 peptide at the C-terminal. 
 
Methods in Peptide Synthesis and Functionalization 
One advantage of peptide synthesis and modification is that once the standard 
protocols are established, peptides with desired sequence, functional groups and 
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structure can be synthesized by the same approach. The methods described 
below apply for both Chapter 1 and Chapter 2. 
Peptide Backbone Construction and Peptide Modification Solid phase 
peptide synthesis (SPPS) can generate short peptides fragments. The maximum 
length of peptide generated by SPPS is around 40 amino acids with useful yield. 
Longer peptides or proteins can be synthesized by recombinant protein expression 
or by ligation of shorter fragments. Among different ligation methods, Native 
Chemical Ligation (NCL) is the most popular method to form a native amide bond 
between the two fragments, by joining a C-thioester peptide fragment to an N-
cysteine modified peptide fragment. 
Installing chemical modifications depends on the nature of the modification. 
Some chemical modifications can be installed during SPPS by using unnatural 
amino precursors. In protein expression, unnatural amino acid mutagenesis can 
be used. Since unnatural amino acid mutagenesis is typically restricted to the 
inclusion of a single non-natural amino acid, we will restrict our discussion to SPPS 
and ligation. If the modification is unstable in SPPS condition or too large and 
sterically hindering to the next coupling reaction in SPPS, other methods such as 
click reactions and cysteine S-alkylation can be used to install those 
modifications.27,28  
Backbone Construction by Solid Phase Peptide Synthesis (SPPS) First 
introduced by Merrifield and co-workers29 in 1963, solid phase peptide synthesis 
(SPPS) has become the most popular synthetic approach for making short 
peptides. The yield of stepwise SPPS decrease as the length of peptide chain 
increases. In general, the maximum length of the peptide with useful yield is 
around 40 amino acids. The use of solid support has huge advantages over 
solution phase peptide synthesis, for the latter often requires purification after each 
standard synthetic cycle and overnight reactions. SPPS eliminates the purification 
steps in each synthetic cycle. SPPS can be accelerated to 4 minutes per synthetic 
cycle,30 and performed by automation at small scale or at industrial scale.31  
Based on the choice of N-terminal protecting group, SPPS can be divided into 
two strategies: tert-butyloxycarbonyl (Boc) strategy and 9H-fluoren-9-yl-
methoxycarbonyl (Fmoc) strategy. The Boc strategy is the original method 
developed by Merrifield, which uses the Boc protecting group as the N-terminal 
protecting group. The Boc group is removed in mild acid condition. The negative 
aspect of the Boc strategy is that it requires the use of hazardous hydrofluoric acid 
(HF) to remove sidechain protecting groups and cleavage from the solid support.29 
On the other hand, the Fmoc strategy uses a base liable N-terminal protecting 
group. The removal of sidechain protecting groups and cleavage from the solid 
support is achieved by treatment with trifluoroacetic acid (TFA), which is a much 
milder condition compare to HF. The Fmoc strategy is more popular than the Boc 
strategy for safety reasons, and the Petersson laboratory uses the Fmoc strategy 
exclusively. Figure 4 shows the typical synthetic cycle of Fmoc based SPPS 
synthesis, where PG stands for a generic side-chain protecting group and AA 
stands for a generic amino acid. The C-terminal amino acid is first attached to the 
resin via a cleavable linker. In the next step, the Fmoc N-terminal protecting group 
is removed by base without removing the acid liable side-chain protecting groups. 
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The peptide chain is extended by coupling the next amino acid after removal of 
reaction side products and excess reagents by rinsing and filtration. The same 
deprotecting and coupling process is cycled until the completion of the entire 
sequence of the peptide. At the end of the cycle, the cleavage from the solid 
support and the side-chain protecting groups are typically removed simultaneously. 
The synthesized crude peptide is often purified by precipitation and High-
performance liquid chromatography (HPLC), then lyophilized to a powder. For 
peptides requiring ligation steps, NCL is often used to link fragments of peptides.  
Backbone Extension by Native Chemical Ligation Developed by Kent and 
co-workers32 in 1994, NCL can be used to ligate two peptide fragments with a 
native peptide bond without epimerization.33 NCL is mostly used to ligate peptides 
that are too long for SPPS or even an expressed protein to a synthetic peptide 
fragment. The main advantage of NCL is its selectivity towards a thioester and N-
terminal cysteine, allowing both peptide fragments to be unprotected. Using 
unprotected peptides eliminates steps for protection/deprotection and prevents 
solubility issues associated with bulky hydrophobic sidechain protecting groups. In 
addition, NCL is a convenient one-pot reaction with a high conversion rate. NCL 
has expanded the application of SPPS and enabled the synthesis of long peptides 
or even full-length proteins. 
Figure 5 shows the steps of the NCL method commonly employed in the 
Petersson laboratory.34,35 Fragment A is a C-terminal modified peptide hydrazide 
generated from modified 2-chlorotrityl chloride resin, fragment B is a peptide with 
an N-terminal cysteine. First, the acyl hydrazide group from the fragment is 
converted to an azide group, then converted to a peptide thioester by 4-
mercaptophenylacetic acid (MPAA) (Figure 5B). Next, the thiol group of the N-
terminal cysteine of fragment B attacks the peptide thioester and forms a native 
peptide bond via an N- to S- acyl shift (Figure 5C). To prepare the peptide 
hydrazide, the 2-chlorotrityl chloride resin is treated with hydrazine hydrate before 
loading the first amino acid, as shown in Figure 5A.35 The SPPS product of 
modified resin gives the C-terminal peptide hydrazide. If the thiol group from the 
cysteine is not desired in the final product, the thiol group can be removed by 
desulfurization.36 Desulfurization greatly extends the possible ligation sites of NCL. 
Besides NCL, there are other traceless peptide ligation methods, such as traceless 
Staudinger ligation37 and methionine ligation.32,38 All ligation methods involve a 
chemo-selective capture step followed by an invariable intramolecular acyl transfer 
reaction. These steps are followed by a final variable step to convert the auxiliary 
to a natural amino acid. 
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Figure 4. Scheme of Fmoc Based SPPS.39  
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Common Peptide and Protein Modification Methods. After the construction 
of the peptide backbone, residues can be modified at various reactive sites. 
Cysteine is a common handle for modifying peptides. There are several 
approaches to conjugate building blocks or modify at the cysteine residue. S-
alkylation and maleimide crosslinking are the two methods that were used in this 
study. Other possible methods include solid phase cross-coupling40 and enzyme-
catalyzed macrocyclization41.  
S-alkylation conjugates the peptide with the fragment of interest at the cysteine 
thiol sidechain, establishing a thioether bond at basic conditions.27 Figure 6 is an 
example of using S-alkylation to couple an alkyne to the cysteine residue sidechain. 
The linker is small but the requirement for basic reaction conditions is not suitable 
for base labile molecules. 
 
Figure 6. S-alkylation of Cysteine Containing Peptide.27 A represents a protein or 
peptide with a cysteine. 
 
Maleimide crosslinking is a common method to label a protein with a biotin or a 
fluorophore.42 This method is also used to generate antibody−drug conjugates for 
cancer treatment.43 The main advantage of maleimide crosslinking reaction is the 
reaction can occur in neutral aqueous conditions. One negative aspect of 
maleimide crosslinking is it leaves a relatively large linker compared to S-alkylation, 
as shown in Figure 7.  
 
 
Figure 7. Maleimide Crosslinking Reaction.43 A represents a labeling reagent with 
the maleimide reactive group; B represents a protein or other molecule that 
contains the target functional group. 
 
Azide-Alkyne Click Chemistry Even though cysteine is a useful handle for 
bioconjugation, selectively labeling peptides or proteins with multiple cysteine 
residues is non-trivial. In this case, click chemistry is another common peptide and 
protein modification method. The term "click chemistry" does not refer to one 
specific reaction, rather, any ligation reaction that is robust, easy to perform, with 
high yield, minimum byproducts formation, and broad substrate spectrum can be 
referred to as a “click chemistry reaction”. The classical click chemistry reaction is 
the copper catalyzed azide-alkyne cycloaddition shown in Figure 8, in which a Cu(I) 
catalyst is generated from Cu(II) in situ.44 The main advantage to this reaction is 
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that there are no azides or alkynes in most biological systems, so this reaction can 
be selective in biomolecules like proteins, and can even occur in vivo without 
perturbing the biological system (although Cu(I) can be toxic).45 More importantly, 
the copper catalyzed click reaction is orthogonal to S-alkylation and maleimide 
crosslinking, which enable us to selectively modify peptides and proteins at 
multiple sites. 
 
 
Figure 8. Scheme of Click Reaction. 46 THPTA refers to 3-
hydroxypropyltriazolylmethyl)amine. 
 
 
 
Figure 9. Mechanisms of Photo-crosslinking.47 (A): benzophenone based 
crosslinking. (B): diazirine based crosslinking. Lig refers generic ligands. 
 
Photo-Crosslinking Probes for Protein-protein Interaction Studies 
Unnatural amino acids can be introduced during SPPS or at modification steps. 
One class of unnatural amino acids is photo-crosslinkers. A photo-crosslinker can 
generate a covalent linkage between the ligand and the binding target based on 
spatial proximity under UV irradiation. The captured target(s) can be isolated and 
identified by mass spectrometry (MS),48 which can be useful in drug design and 
protein function studies. Common photo-crosslinkers can be characterized into 
three families: benzophenone, aryl azide, and diazirine. These photo-crosslinking 
groups have differing selectivity and reactivities.47 The mechanism of 
benzophenone and diazirine crosslinking is shown in Figure 9. In both cases, UV 
irradiation generates a reactive radical, but the homolytic bond cleavage of 
benzophenone is reversible, allowing it to return to the ground state if no reactive 
partner is present.  On the other hand, the expulsion of N2 in diazirine photolysis 
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makes it irreversible, so the resulting carbene is much more reactive. Thus, 
benzophenones are more selective crosslinkers. 
Using the methods of peptide synthesis and modification mentioned above, I 
synthesized a series of probes to study the functions of histone H4 N-terminal 
acetylation (N-ac) in project 1. The result of project 1 can help explaining the role 
of histone co- and post-translation in gene regulation. In project 2, I synthesized a 
different set of probes to study the toxicity mechanism of proline-arginine tandem 
repeat peptides PRx. The result of project 2 can provide mechanism foundation for 
developing amyotrophic lateral sclerosis (ALS) treatments.  
 
Materials and Methods 
 
SPPS Materials Fmoc-Lys(biotinyl)-OH was purchased from TCI America 
(Portland, OR, USA). Fmoc-PhotoLys(Boc)-OH was kindly provided by Dr. Xiang 
David Li from the University of Hong Kong (Hong Kong, China). 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 2-
Chlorotrityl chloride resin (100-200 mesh, 1% DVB) were purchased from 
Novabiochem (currently EMD Millipore; Billerica, MA, USA). Standard amino acids 
for Fmoc peptide synthesis were also purchased from Novabiochem (currently 
EMD Millipore; Billerica, MA, USA), including Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, 
Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-
OH and Fmoc-Pro-OH. Piperidine was purchased from American Bioanalytical 
(Natick, MA, USA). Sigmacote®, N,N-diisopropylethylamine (DIPEA), and 
Trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Glass peptide synthesis reaction vessels (RVs) were treated with 
Sigmacote® prior to use. Triisopropylsilane (TIPS) was purchased from Santa 
Cruz Biotechnology (Dallas, TX, USA). N-Methylmorpholine (NMM) and 4-
mercaptophenylacetic acid were purchased from Acros (Currently Fisher Scientific, 
Hampton, NH, USA). Acetic anhydride, hydrazine hydrate (55% in water), Bond-
Breaker™ TCEP Solution, Ellman’s reagent, Acetonitrile (ACN), 
Dimethylformamide (DMF), Methanol (MeOH) and Tetramethylrhodamine-5-
Maleimide (TAMRA) were purchased from Fisher Scientific (Hampton, NH, USA). 
Guanidine hydrochloride (Gn·HCl) was purchased from Invitrogen (Carlsbad, CA, 
USA) Cys(ProArg)20 peptide was purchased from GenScript (Piscataway, NJ, 
USA).  
Instruments Histone H4 peptide residues 1 to 18 was synthesized using a 
Liberty synthesizer (CEM Corporation, Matthews, NC). Crude peptides were 
purified with a Varian ProStar High-Performance Liquid Chromatography (HPLC) 
instrument outfitted with a diode array detector (currently Agilent Technologies) 
using aqueous A (H2O + 0.1% TFA) and organic B (CH3CN + 0.1% TFA) phases. 
Purification testing was performed in an Agilent 1100 Series HPLC with a 4.6nm 
Phenomenex Luna C8 (2) column. 
UV absorbance spectra were obtained with a Hewlett-Packard 8452A diode 
array spectrophotometer (currently Agilent Technologies; Santa Clara, CA, USA). 
Matrix-assisted laser desorption ionization (MALDI) mass spectrometry (MS) data 
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were collected with a Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer 
(Billerica, MA, USA). 
Reagent Setup TFA cleavage cocktail A: TFA/DCM/TIPS/Water=90/5/2.5/2.5 
(vol/vol/vol/vol) TFA cleavage cocktail B: TFA/DCM/TIPS/Water=85/10/2.5/2.5 
(vol/vol/vol/vol) TFA cleavage cocktail C: TFA/DCM/TIPS/Water=30/65/2.5/2.5 
(vol/vol/vol/vol) Acylating cocktail: DMF/NMM/acetic anhydride=84/6/10 
(vol/vol/vol/vol) 5% Hydrazine in DMF: 0.4 mL of hydrazine hydrate was mixed with 
7.6 ml of DMF. TAMRA-maleimide in DMSO: TAMRA-maleimide was dissolved in 
DMSO to a final concentration of 4.5 mM. Two different phosphate solutions (0.2M) 
containing 6M Gn•HCl (pH 3.0-3.1 and pH 6.9-7.0, respectively): For a 10-ml 
solution, 312 mg of NaH2PO4•H2O and 5.74 g of Gn•HCl was mixed into a 15-ml 
centrifuge tube and pH was adjusted to 3.0-3.1 and 6.9-7.0 with 6M NaOH and 1M 
HCl. The solution was filtered by 0.22 µm microporous membrane filter. NaNO2, 
0.5M: 17mg of NaNO2 was dissolved in 0.5 ml of water before use.  50% ACN in 
water with 0.1%TFA: 5 ml of water, 5ml of CAN and 10 µl of TFA were mixed. -
15 °C ice bath was prepared by mixing 12.5 g of NaCl with 25 g of ice. Milli-Q 
filtered (18 MΩ) water was used for all solution preparations (EMD Millipore, 
Billerica, MA, USA). 
Standard Synthesis Cycle Standard synthesis cycle was used for all 
deprecating and coupling reactions except the first amino acid and unnatural 
amino acids. In each synthesis cycle, the resin was washed three times with 
(dimethylformamide) DMF under gentle agitation. Followed by three washes of 
dichloromethane (DCM) and another three washes of DMF. To remove the Fmoc 
deprotecting group, 2 ml of 20% piperidine in DMF (vol/vol) was added to the 
reaction vessel (RV) and agitated for 20 minutes. Then the resin was drained and 
washed with the same DMF-DCM-DMF sequence as mentioned above. For each 
25 µmol scale synthesis, 125 µmol (5 equiv) of the appropriate amino acid and 
125µmol of HBTU (5 equiv) was dissolved in 2 ml of DMF, with 44 µl of DIPEA (10 
equiv) added. This step pre-activates the amino acid and usually gives the solution 
a light-yellow color. The fully dissolved amino acid solution was then added to the 
RV. The coupling reaction time is 30 minutes. This cycle was repeated until the full 
length of peptide is synthesized. After the last amino acid coupling, step 1-6 was 
performed to remove the Fmoc group. 
Synthesis of PR3 and PR5 Peptides 7, 8 PR3 and PR5 peptides were 
synthesized in 25 µmol scales each, using 2-Chlorotrityl chloride resin under 
standard SPPS condition. To couple on the first amino acid, 42mg of 2-Chlorotrityl 
chloride resin (estimated resin loading capacity of 0.6mmol/g) was added to a dry 
reaction vessel (RV) with prior Sigmacote® treatment. Then the resin was washed 
with DMF and then swelled in DMF for two successive of 15 minutes with gentle 
agitation. Then 125 µmol (5 equiv) of Arg(Pbf) was dissolved in 2 ml of DMF, then 
the amino acid solution and 44µL of DIPEA (10 equiv) were added to RV. The 2-
Chlorotrityl chloride resin does not require HBTU in the first amino acid coupling 
step. The coupling time was 30 minutes. The rest of the sequence was synthesized 
using the Standard Synthesis Cycle. After the final Fmoc deprotection, the resin 
was drained and dried by vacuum filtration. To remove the Pbf protecting group 
and cleaved from the resin, 2ml of TFA cleavage cocktail A was added to the RV 
14 
 
and agitated for 90 minutes. At the end of the cleavage, the cleavage solution was 
collected from the bottom of the RV, and then two small amounts of DCM were 
added to rinse the RV. The combined cleavage solution was concentrated by a 
rotavapor. The concentrated peptide was diluted to 5 ml with 50% ACN in water 
with 0.1%TFA. The crude peptide was then filtrated with a 0.20µM syringe filter to 
remove solid particles before HPLC purification. 
PR3 and PR5 Peptide Purification and Characterization The crude peptides 
were purified by reverse-phase HPLC using a Vydac 218TP C18 prep column 
(Grace/Vydac; Deerfield, IL, USA). The flow rate was 15 ml/min, the gradient was 
2%B in 0-5 min, 2-10%B in 5-10 min, 10-40%B in 10-40 min, 40-100%B in 40-45 
min, 100%B in 45-50 min, and 100-2%B in 50-55 min, where A is water with 0.1% 
TFA and B is ACN with 0.1% TFA. Fractions were tested by MALDI-MS, fractions 
with pure peptide were combined and lyophilized. The lyophilized products were 
dissolved with 5.2 ml of 50% ACN in water (0.1%TFA), then 5 ml of the solution 
was transferred to five microcentrifuge tubes with 1 ml solution in each tube. The 
microcentrifuge tubes were dried down with a table top vacuum centrifuge 
(Savant/Thermo Scientific; Rockford, IL, USA). The rest of the solution was used 
for MALDI characterization and analytical HPLC analysis. For HPLC 
characterization, the sample was diluted to 800 µL final volume with water with 0.1% 
TFA. MALDI characterization was performed using standard instrument set-up 
under positive mode with reflector enabled, using α-Cyano-4-hydroxycinnamic 
acid (CHCA) matrix. HPLC analysis was performed using a 4.6mm VYDAC HPLC 
C18 column from Grace Davison Discovery Science at 1 ml/min flow rate, 
measuring absorbance at 215 nm, using the same gradient in protein preparation. 
Systhesis of Histone H4 Peptides 1, 2 Synthesis of Histone H4 peptide uses 
the synthesis cycle as above, with minor differences in certain amino acids 
coupling steps mentioned below. For Lys(biotinyl), 3 equiv of the amino acids for 
coupling reaction was used. For Photo-Lysine, we used 2 equiv of the amino acids 
in coupling reactions. 5 equiv of the Fmoc amino acids for all other amino acids. 
Residues 2-18 were synthesized by the Liberty peptide synthesizer following 
manufactory’s procedures. For the first amino coupling, 84mg of 2-Chlorotrityl 
chloride resin was added to a dry reaction vessel (RV) with prior Sigmacote® 
treatment. 5 ml of 50% DMF in DMSO was added with magnetic stirring for two 
successive of 15 minutes to swell the resin, then drained by vacuum filtration. Next, 
120 mg of Fmoc-Lys(Biotin)-OH was added to 6 ml of 50% DMSO in DMF. To help 
solubilization of the amino acid, the solution was warmed in 37 °C water bath for 
about 15 minutes. 3 ml of the amino acid solution and 175 µl of DIPEA were added 
to the RV. After 45 minutes of coupling, the resin was drained by vacuum filtration. 
The rest of Fmoc-Lys(Biotin)-OH solution and 175µl of DIPEA were added to the 
RV. After 45 minutes of coupling, the resin was drained and washed by the DMF-
DCM-DMF sequence as mentioned before. After loading the first amino acid to the 
resin, the resin was swelled in 6 ml of DMF for 30 minutes then drained. To 
deactivate the unreacted site on the resin, a capping procedure was performed by 
adding 2 ml of 10% MeOH/DMF and 175 µl of DIPEA to the RV. The capping 
reaction was 20 minutes and then the resin was washed with the DMF-DCM-DMF 
sequence. Next, the resin was transferred from the RV to the Liberty peptide 
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synthesizer to synthesize residues 2-18 using manufacturer’s standard method. 
After the 18th residue, the resin was removed from the peptide synthesizer and 
manual synthesis was performed using the standard synthesis cycle, since the 
photo-lysine is a light sensitive amino acid, the handling of photo-lysine and 
reaction steps after photo-lysine coupling reaction were performed under red LED 
with the RV covered with aluminum foil. After the final Fmoc deprotection reaction, 
half of the resin was acetylated at N-terminal, giving the N-acetylated Histone H4 
peptide. The other half of the resin undergoes cleavage directly. To acetylate the 
peptide at the N-terminal. Two portions of 5 ml of the acylating cocktail were added 
to the RV and agitated for 20 minutes with washing in between. To cleave the 
peptide from the resin and remove the protecting groups, 2 ml of TFA cleavage 
cocktail B was added to the RV and agitated for 90 minutes. At the end of the 
cleavage, the cleavage solution was collected from the bottom of the RV, and then 
two small amounts of DCM were added to rinse the RV. The cleavage solutions 
were then concentrated using a rotavapor. The concentrated peptide solution was 
transferred to a 15-ml centrifugal tube, and then about 10 ml of cold ether was 
added to precipitate down the crude peptide. The volume of cold ether should be 
at least 10 times larger than the concentrated peptide solution. The peptide was 
incubated at 4 °C for 20 minutes and then centrifuged for 5 minutes. The 
supernatant was discarded and the pellet was dissolved in minimal amount of 50% 
ACN in water with 0.1%TFA. The crude peptide was then filtrated with a 0.20µM 
syringe filter to remove solid particles before HPLC purification. 
Peptide Purification and Characterization The crude peptides were purified 
by reverse-phase HPLC using a Vydac 218TP C18 prep column (Grace/Vydac; 
Deerfield, IL, USA). The flow rate was 15 ml/min, the gradient was 2%B in 0-5 min, 
2-10%B in 5-10 min, 10-40%B in 10-40 min, 40-100%B in 40-45 min, 100%B in 
45-50 min, and 100-2%B in 50-55 min, where A is water with 0.1% TFA and B is 
ACN with 0.1% TFA. Fractions with pure peptide were combined and lyophilized. 
The lyophilized products were dissolved with 5.2 ml of 50% ACN in water 
(0.1%TFA), then 5 ml of the solution was transferred to five Eppendorf tubes with 
1 ml solution in each tube. The Eppendorf tubes were dried down by a table top 
vacuum centrifuge (Savant/Thermo Scientific; Rockford, IL, USA). The rest of 
solution was used for MALDI characterization and analytical HPLC analysis. For 
HPLC characterization, the sample was diluted to 800µL final volume with water 
(0.1% TFA). MALDI and HPLC characterization was performed using the same 
condition as for PR3 and PR5 peptides. 
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Synthesis of TAMRA-PR20 Probe 3 Crude Cys(PR)20 peptide solid was 
purchased from GeneScript (Piscataway, NJ, USA) and purified by reverse-phase 
HPLC using a Vydac 218TP C18 prep column (Grace/Vydac; Deerfield, IL, USA). 
The flow rate was 12 ml/min, the gradient was 2%B in 0-5 min, 2-10%B in 5-10 
min, 10-40%B in 10-40 min, 40-100%B in 40-45 min, 100%B in 45-50 min, and 
100-2%B in 50-55 min. The purified peptide was lyophilized. Quantification was 
performed by using Ellman’s reagent following Sigma-Aldrich manual #22582, with 
the exception that pretreatment with immobilized TCEP was not performed. 0.2 
mmol of Cys(PR)20 peptide was dissolved in 900 µl of 20 mM Tris buffer, pH 8. 0.5 
µl of TCEP bond breaker and 36 µl of TAMRA-maleimide in DMSO was added. 
The reaction was performed at room temperature with magnetic stirring, using 
MALDI-MS to monitor the reaction process. The labeled peptide 3 was purified 
using the same condition for Cys(PR)20 peptide, followed by characterized with 
MALDI-MS with expected m/z of 5652. 
 
 
Preparation of Hydrazine Modified 2-Chlorotrityl Chloride Resin The 
warhead 4 was synthesized by SPPS using hydrazine modified 2-Chlorotrityl 
chloride resin. First, 100 mg of 2-Chlorotrityl chloride resin was added to a dry 
reaction vessel (RV) with prior Sigmacote® treatment. The resin was swelled by 
DMF for two successive of 15 minutes. Then, the resin is treated with two 
successive of 4 ml of 5% (vol/vol) hydrazine in DMF for 20 minutes under gentle 
agitation. The resin was washed with DMF and then DCM carefully.  
  
17 
 
 
 
Synthesis of Warhead 4 To couple the first amino acid, 125 µmol (5 equiv) of 
the appropriate amino acid and 125 µmol of HBTU (5 equiv) was dissolved in 2 ml 
of DMF, then 44 µl of DIPEA (10 equiv) was added to the amino acid solution. The 
amino acid solution was added to the RV and agitated for 30 minutes. The rest of 
the sequence was synthesized by standard synthesis cycle. The cleavage and 
purification condition was identical to the PR3 peptide. The expected m/z is 752, 
monitored by MALDI-MS. 
 
 
Synthesis of Molecule 5 0.6 µmol of peptide hydrazide 4 was dissolved with 
0.4 ml of 0.2M phosphate buffer (pH 3) in a 2 ml microcentrifuge tube. pH was 
adjusted to 3.0-3.1 with 6M NaOH and 1M HCl. The microcentrifuge tube was 
incubated on -15 °C ice bath for 15 minutes. Around 0.5 µmol of Cys(PR)20 peptide 
and 13.6 mg of MPAA (4-Mercaptophenylacetic acid were dissolved in 0.4 ml of 
pH 7 phosphate buffer and adjusted pH to 6.5. To oxidize the peptide hydrazide to 
azide, 40 µl of 0.5M NaNO2 solution was added to the solution of compound 4. The 
pH of the mixture was adjusted to 3-3.1 and stirred for 15 minutes in -15 °C ice 
bath. To convert the peptide azide to thioester, Cys(PR)20 and MPAA mixture 
solution was added to peptide azide 4. The microcentrifuge tube was removed 
from ice bath and warmed to room temperature. pH was adjusted to 6.8-7.0 with 
6M NaOH. After overnight stirring at room temperature, 80 µl of TCEP bond 
breaker was added. The mixture was diluted to 5 ml final concentration before 
HPLC purification. For MALDI-MS characterization, 1 µl of the reaction mixture 
was diluted 30 times with water. The product 5 was purified using the same HPLC 
gradient to compound 3 and then lyophilized. The expected m/z is 5908. 
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S-Alkylation 4 Lyophilized peptide 5 was dissolved in a round bottom flask with 
1 ml of MeOH. With stirring, 10 µl propargyl bromide, 5 µl of DIPEA and 1 mg of 
TCEP was added to the flask. The reaction progress was monitored by MALDI-MS 
until finished. When the reaction is finished, MeOH was removed by a rotary 
evaporator and product 4 was dissolved in 50% ACN in water and then purified by 
HPLC using the same gradient to compound 3. The expected m/z is 5976. 
Peptide Characterizations All peptides were characterized with MALDI-MS as 
shown in Table 1. For all peptides, expected m/z was observed, which suggests I 
have successfully synthesized the peptides of interest. 
 
Table 1. Characterizations of Synthetic Peptides 
Molecule Calculated (+m/z)  Measured (+m/z)  
3 5652 5652 
4 752 752 
5 5908 5908 
6 5976 5976 
7 778 778 
8 1284 1284 
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Results and Discussion 
 
Project 1: Interactions of N-Terminally Acetylated Histones 
For comparison between the non-acetylated histone H4 peptide and N-ac 
histone H4 peptide, two versions of the probe was designed. The non-acetylated 
version is referred to as compound 1 and N-ac version as compound 2. The 
sequence is R-Ser-Gly-Arg-Gly-PhotoLys-Gly-Gly-Lys-Gly-Leu-Gly-Lys-Gly-Gly-
Ala-Lys-Arg-His-Arg-Lys-Gly-Gly-Lys(Biotin)-COOH. R refers to a hydrogen atom 
for non-acetylated histone peptide H4 probe 1 and an acetyl group for N-ac histone 
peptide H4 probe 2. The structures are shown in Figure 10. 
Peptide 1 and 2 were synthesized by SPPS and characterized by MALDI-MS. 
We observed m/z of 2457 and 2499 for compound 1 and 2 on MALDI-MS, 
respectively. This two masses correspond to [M+H]+ minus 28 Da, the minus 28 
Da is the loss of two nitrogen atoms from diazirine functional group, which is 
expected for the unstable crosslinking group.49 The MS data confirmed that I have 
successfully synthesized the peptides of interest, and the peptides were used in in 
vitro crosslinking experiments. 
Cell Lysate Western Blot The cell lysate crosslinking test was performed by 
Gleb Bazilevsky in the Marmorstein group and the result is shown in Figure 11. In 
brief, the probes were incubated with cell lysates under UV irradiation, then a 
streptavidin Western blot was performed to image the captured protein(s). The 
photo-crosslinking experiments were performed with E. coli cell lysate and Hela 
cells lysate, respectively. In the E. coli cell lysate pull-down experiment, no 
difference was observed between the treatment with peptide 1 and 2, indicating no 
protein shows binding preferences between the two versions of histone H4 peptide 
in E. coli. The result that proteins from prokaryotic E. coli do not bind to the histone 
H4 peptide meets the expectation since histone proteins only exist in eukaryotic 
organisms. Thus, this serves as an effective negative control for non-specific 
binding of the peptides. For the HeLa cell lysate pull-down experiment, a few bands 
were found only in lane 12 (the N-ac H4 peptide) but not in lane 10 (the non-
acetylated H4 peptide). This suggests that proteins bind exclusively to the N-ac H4 
peptide. The identities of the protein bands have not yet been determined by MS. 
It is concerning that many of the bands in lane 12 are also present in lane 11, non-
irradiated N-ac H4 peptide. Further experiments are necessary to fully characterize 
these interactions. I hypothesize that the identified protein might be an enzyme 
that can remove the N-terminal acetyl group or a transcription factor. 
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Figure 11. Cell lysate Western Blot experiment. Lane 1 to 6 is E. coli lysate with 
either 0 or 30 min UV irradiation. Lane 7 to 12 are HeLa cell lysate with either 0 or 
30 min UV irradiation. Lane 1: cell lysate only, no probe, 0 min; Lane 2 cell lysate 
only, no probe, 30 min; Lane 3: none-acetylated H4 peptide, 0 min; Lane 4: non-
acetylated H4 peptide, 30 min; Lane 5: N-ac H4 peptide, 0 min; Lane 6: N-ac H4 
peptide, 30 min; Lane 7: no peptide, 0 min; Lane 8: no peptide, 30 min; Lane 9: 
non-acetylated H4 peptide, 0 min; Lane 10: non-acetylated H4 peptide, 30 min; 
Lane 11: N-ac H4 peptide, 0 min; Lane 12: N-ac H4 peptide, 30 min. (Bazilevsky, 
G. University of Pennsylvania, PA, USA. Unpublished work, 2016) 
  
 1   2   3  4   5  6  7   8   9 10 11 12 
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Project 2: Binding Study of (PR)x Peptide to Proteasome  
 
PR20 Probe for Cell Imaging Several peptides were synthesized to investigate 
the toxic effects of (PR)X peptides, including their localization in cells and their sites 
of interaction with the proteasome. To perform a fluorescence microscopy imaging 
study, probe 3 was designed and synthesized to monitor the location of the peptide 
in cells. This probe can also be used to determine the affinity of the probe for 
purified proteasomes using flurescemce polarization. This probe consists of the 
PR20 peptide with a fluorophore attached at one end. In probe 3 design, a 
tetramethylrhodamine-5-Maleimide (TAMRA) fluorophore (highlighted in red) is 
linked to the N-terminal cysteine of the PR20 peptide via maleimide crosslinking 
(Figure 12). I chose TAMRA as the fluorophore because of its red fluorescence 
can be distinguished from the GFP labeled proteasomes expressed in cells. The 
proposed experiment is to add TAMRA-labeled probe 3 to the cell growth media, 
and the cellular uptake and localization of probe 3 can be monitored by a confocal 
microscope. Colocalization of probe 3 with the proteasome in cells can support the 
proteasome toxicity theory. 
 
 
Figure 12. Synthesis Route of TAMRA-PR20 Probe 3 
 
Development of Photo-Crosslinking PR20-X Probe To verify the hypothesis 
that the PRx peptide can bind to certain subunit(s) of the proteasome, a second 
probe was designed and synthesized, which consists of a PR20 peptide, a photo-
crosslinker, and a biotin affinity purification tag. The identification of the binding 
site(s) can provide critical information on the molecular mechanism of PR20 toxcity. 
It could also be used in design of PR20 peptide binding antagonists, a potential 
treatment for ALS. 
Previously, Xing Chen from the Petersson group synthesized a photo-
crosslinking probe by using NCL to ligate a PR20 peptide to a “warhead”. The 
warhead is a short peptide containing a biotin (highlighted in red) and a 
benzophenone group (highlighted in blue), with a glycine residue in between each 
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functional motif (Figure 13). This probe is referred to as the PR20-X probe. I 
synthesized a batch of the PR20-X probe as a replicate to Xing Chen’s work. 
 
 
 
Figure 13. PR20-X Probe Design. (Petersson laboratory, University of 
Pennsylvania, PA, USA. Unpublished work, 2016). 
 
Development of Photo-Crosslinking Probe with a Bio-orthogonal Handle 
In the PR20-X probe design, the warhead is linked to the C-terminal end of the PR20 
peptide. One negative aspect of this probe design is there is a cysteine residue in 
the sequence, and the cysteine thiol group can potentially form disulfides or bind 
to the proteasome non-specifically. To overcome this problem, probe 4 was 
designed to verify the result obtained from using the PR20-X probe (Figure 14). 
Probe 4 has similar functional groups to PR20-X, but the warhead is linked to the 
N-terminal end instead of the C-terminal end of the PR20 peptide. If the proteasome 
binding patterns of PR20-X and 4 are consistent, we can conclude that the binding 
of the PR20 peptide to the proteasome subunits is not an artifact due to the 
placement of warhead. Otherwise, the probe design must be modified so that the 
probe does not perturb the function of the PR20 peptide. Probe 4 also contains a 
click reaction handle at the cysteine residue, so that the cysteine thiol group can 
be neutralized. Neutralizing this reactive thiol group not only prevents non-specific 
binding but also provides a click handle for fluorophore attachment. The 
fluorophore attached probe 4 can be a substitute to probe 3. For the photo-
crosslinker, benzophenone was chosen because benzophenone is more stable 
than the diazirine photo-crosslinker used in project 1, and therefore the peptide 
probe is likely to have selective crosslinking. The peptide is also more stable under 
ambient light.  
The synthesis route of 4 is summarized in Figure 14. First, warhead 5 was 
synthesized by SPPS, then 5 was ligated with the Cys(PR)20 peptide to form 
compound 6, followed by S-alkylation with propargyl bromide to form the final 
product 4. I expected that probe 4 could bind to certain proteasome subunit(s) in 
the same manner as PR20-X. The band from the blotting experiment can be further 
analyzed by MS to identify the proteasome subunit. 
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Figure 14. Synthesis Route of Warhead-PR20 Probe 4 
 
The preparation of the PR20 peptide suffers from low yield and difficulties in 
quantification. I initially synthesized the PR20 peptide by using a CEM Liberty 
peptide synthesizer but less than 1% yield product was recovered. One reason for 
the low yield is the length of the PR20 peptide is at the maximum limit of SPPS. As 
the peptide chain grows, the polymer may aggregate or become sterically 
inaccessible, and prevents further chain extension. Another reason is that the 
arginine 2,2,4,6,7-Pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) protecting 
group is not very acid lable, the removal of Pbf groups requiring prolonged 
treatment of high concentration TFA. However, the same condition can also 
hydrolyze the peptide backbone, so the deprotection time was limited to a few 
hours. As a result, we observed incomplete deprotection by-products from the 
crude peptide, having an m/z of 252 Da or 504 more than the expected mass. 1,2-
Dimethylindole-3-sulfonyl (MIS) was reported to be a more acid lable substitution 
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for the Pbf group, but there is no commercially available Fmoc-Arg(MIS)-OH amino 
acid in the market as of 2017.50   
In probe 4 synthesis, the Cys(PR)20 peptide was quantified by Ellman’s reagent 
without pretreatment. According to Ellman’s reagent standard protocols (Sigma-
Aldrich manual #22582), the peptide should be treated by immobilized TCEP to 
remove possible disulfide bonds. However, I could not elute the peptide from the 
immobilized TCEP resin. The most likely reason is that the guanidinium group from 
the arginine sidechain binds to the resin tightly, preventing elution from the resin. 
Without TCEP treatment, the quantification will underestimate the concentration of 
the Cys(PR)20 peptide. To compensate for this problem, I used an excess amount 
of the compound 5 during the NCL process. 
Figure 15. PR20 Peptide Crosslinks to Proteasome Subunits. Lane 1: proteasome 
crosslinked with the PR20-X probe. Lane 2: same to lane 1 plus excess unlabeled 
PR20 peptide to compete off PR20-X probe binding. Lane 3: proteasome 
crosslinked with the PR20-X probe plus an excess amount of unlabeled GR20 
peptide. Lane 4: Coomassie stained proteasome subunits. The red boxes indicate 
the corresponding bands from lanes 1 and 2 to lane 4. (Kalb, R. Children's Hospital 
of Philadelphia, PA, USA. Unpublished work, 2016). 
Proteasome Binding Assay The proteasome binding assay using the PR20-X 
probe was performed by the Kalb group from the Children's Hospital of 
Philadelphia. Figure 15 is a streptavidin Western blot of proteasome subunits, 
where the probes and the cell lysate were crosslinked by UV irradiation, then 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS 
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Page) (Kalb, R. Children's Hospital of Philadelphia, PA, USA. Unpublished work, 
2016). The three clear bands in lane 1 suggested that three proteasome subunits 
can bind to the PR20-X probe, labeled as 1, 2, and 3. The bands are less intense 
in lane 2, suggesting excess unlabeled PR20 can compete with PR20-X for 
proteasome binding sites, confirming that the PR20-X probe behaves similarly to 
the unlabeled PR20 peptide. The patten of bands in lane 3 is similar to lane 1, 
suggesting that the GR20 peptide cannot compete with PR20-X for proteasome 
binding sites. This result agrees with the fact that the GR20 peptide is non-toxic 
while the PR20 peptide is highly toxic.26 This result indicates the PR20 peptide can 
bind to the proteasome subunits while the non-toxic GR20 peptide can not. 
The three bands indentifed by the blotting experiment was anlyzed by the 
Proteomics Core Facility at the Children’s Hospital of Philadelphia (CHOP) 
Research Institute. Serveal protein candidates were identified based on the 
molecular weight of the protein target (Table 2).51 The binding pattern is not 
obvious according to the MS result. I hypothesize that all subunits that bind to the 
PR20 peptide have a common motif, but further experiments with probe 4 is needed 
to confirm the crosslinked protein identities and to explain the binding mechanism.  
 
Table 2. Crosslinked Proteasome Proteins Candidates 
Band 
Number candidate proteins 
molecular 
weights 
(Kda) 
UniProt 
accession 
numbers 
Band 1 
26S protease regulatory subunit 4  49 P62191 
26S proteasome non-ATPase     
regulatory subunit 2  100 Q13200 
Band 2 
26S proteasome non-ATPase 
regulatory subunit 11 47 O00231 
Isoform 2 of 26S protease regulatory 
subunit 8  45 P62195-2 
Band 3 
Proteasome subunit alpha type-6 27 P60900 
Proteasome subunit alpha type-3 28 P25788 
Proteasome subunit alpha type-5 26 P28066 
Proteasome subunit beta type-7  30 Q99436 
Proteasome subunit alpha type-7  28 O14818 
 
Source: Adapted from Lan, M. The Role of the Proline-Arginine Dipeptide Repeat in 
Amyotrophic Lateral Sclerosis. M.S. Dissertation, University of Pennsylvania, Philadelphia, 
PA, USA, 2017. 
Binding Competition of PRx Peptides with Different Lengths The final goal 
of this project was to verify if the length of the PRx peptides determines the binding 
activity and toxicity. In most previous studies, the PR20 peptide was used as the 
model for toxic PRx.24,26 This gave rise to the question if the length of PRx peptides 
can have effects in proteasome binding. To answer this question, I synthesized 
two unlabeled versions of PRx peptide: (Pro-Arg)3 (7) and (Pro-Arg)5 (8) in this 
project (Figure 16). A binding competition assay using 7 and 8 against the PR-X 
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probe was performed to determine if peptide 7 and 8 can bind to the proteasome 
and compete out the PR20-X probe (Kalb, R. Children's Hospital of Philadelphia, 
PA, USA. Unpublished work, 2017).  
Binding Competition Assay The binding competition assay was performed by 
incubating the PR20-X probe, PR3 (7) and PR5 (8) peptides with proteasome 
subunits. Then the mixture was crosslinked by UV irradiation followed by avidin 
Blot (Figure 17). Lane 2 and lane 3 indicated the natural PR20 peptide could 
compete out the PR20-X probe in proteasome binding. This serves as a control to 
prove that the PR20-X probe and PR20 peptide have binding affinity. It can be 
observed that the PR3 and the PR5 peptides do not compete with the PR20-X probe 
to bind to the proteasome, as indicated by comparing lane 2 to lanes 6 and 7. This 
suggested that PRx peptide binding to the proteasome is length dependent and 
sufficiently cooperative; multiple PR3 or PR5 peptides cannot simply occupy the 
binding site for PR20. 
 
 
 
Figure 16. The Structure of PR3 Peptide 7 (top) and PR5 Peptide 8 (bottom) 
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Figure 17. Binding Competition Assay by Streptavidin Blot. Lane 1 to 7 (left to right) 
represents: ladder; PR20-X probe with proteasome; PR20-X peptide with 
proteasome with extra PR20 peptide; GR20-X peptide with proteasome; identical to 
lane 3 but with extra incubation time before UV irradiation; PR3 peptide and PR20-
X probe with proteasome; PR5 peptide and PR20-X probe with proteasome. All 
samples were irradiated by UV at 365 nm for 30 min for crosslinking before the 
streptavidin blot. The red boxes indicate the same bands as in Figure 15. (Kalb, 
R. Children's Hospital of Philadelphia, PA, USA. Unpublished work, 2017) 
 
Conclusion and Future Work 
 
To summarize this study, our synthetic probes provided tools to study the 
mechanism of ALS disease and histone function in vitro or in cells. In project 1, I 
used SPPS to synthesize two 23-mer probes 1 and 2 to perform a crossslinking 
experiment to identify the protein(s) that bind to an N-ac histone H4 peptide. In the 
blotting experiment, some protein targets were found with binding preference to 
the N-ac histone peptide. The next step would be to replicate these results and 
use MS to identify the proteins. In project 2, I synthesized another set of probes, 
including a 41-mer TAMRA fluorophore labeled PR20 peptide 3, and a 46-mer PR20 
peptide with a photo-crosslinking warhead probe 4, a 6-mer PR3 peptide 7, and a 
10-mer PR5 peptide 8. This set of probes were synthesized for the study of the 
toxicity mechanism of PRx peptide. The preliminary in vitro result demonstrated 
that the length of the PRx peptide plays in role in proteasome binding. The PRx 
peptide binds to the proteasome with a defined pattern. The probes 3 and 6 will be 
tested by the Kalb group.  
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PRx Peptide Synthesis by Recombinant Protein Expression Peptides in the 
30 to 40 amino acid range are usually too short for protein expression and are 
generated by SPPS. In my syntheses of the PR20 peptide by SPPS, I found the 
yields to be low due to the difficult removal of arginine Pbf sidechain protection 
groups. To synthesize unconventional peptides like the PRx peptides, we would 
like to use recombinant protein expression to synthesize the peptide. Purification 
tags can facilitate protein expression and stabilize the peptide. Previously, the 
Petersson laboratory successfully used an intein as a traceless purification tag to 
express α-synuclein (140 amino acids) containing the unnatural amino acid p-
cyanophenylalanine at position 136 using orthogonal aminoacyl-tRNA 
synthetase/tRNA pairs.52,53 I could use inteins and the Small Ubiquitin-like Modifier 
(SUMO) proteins as a generalizable purification tag for medium size peptides that 
are unsuitable for NCL, but too long for efficient SPPS.  
We performed the preliminary experiment of PR20 peptide biosynthesis but the 
result was unsuccessful. We transformed pET His6 Sumo TEV CPR20 plasmid 
(Appendix A) into E. coli. BL21(DE3). Figure 18 shows the sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS Page) gel image of the SUMO-
CPR20 fusion protein expression and Ni column purification elution, stained with 
Coomassie blue. Lane 1 and 2 is the cell lysate before and after transformation but 
before Isopropyl β-D-1-thiogalactopyranoside (IPTG) induction, respectively. The 
intense induction band near to the top of the gel at lane 2 suggests the fusion 
protein can be readily induced by IPTG. However, the induction band could not be 
observed in lane 3, which is from to harvested cell lysate and Ni column purification 
elution, respectively. The loss of the induction band suggests that the target protein 
was lost during the process of cell harvesting. We believe this is because the PR20 
fusion protein has a high arginine content. It was known that arginine has a high 
binding affinity towards nucleic acids, so a protein with high arginine content is 
likely to precipitate with other cellular components during cell harvesting process.54 
To overcome this problem, we need to find the cell lysing condition that prevents 
Arginine from binding to nucleic acid. The addition of glycerol and high 
concentration of potassium chloride into the cell lysing buffer can prevent the 
interactions between arginine-rich peptides and nucleic acid (Skordalakes, E. 
Wistar Institute, Philadelphia, PA. Personal communication, 2017.). This strategy 
will be tested in the future. 
 
 
 
 
Figure 18. SDS Page of His6-SUMO-CysPR20 Fusion Protein Expression and Ni 
Column Purification. 
 
 
 
30 
 
Chapter 2  
Thioamide as a Proteolysis-resistant Modification 
 
Introduction 
 
Importance and Significance Peptide-based medicine has a wide range of 
applications and huge value in marketing. The global annual sale of peptide-based 
medicine was $14.1 billion in 2011 and was predicted to be $25.4 billion in 2018.55 
One of the challenges to peptide-based medicine is that most naturally occurring 
peptides are susceptible to proteolysis in plasma and have a very short half-life. 
For example, the incretin hormone glucagon-like peptide-1 (GLP-1) has a half-life 
of 1.5 to 5 minutes in plasma.56 The use of peptide cyclization, D- and β-amino 
acids substitution can stabilize peptides in plasma.57,58 These three approaches 
have had success in the past but they all change the structure or conformation of 
the target molecules, which may lead to unpredictable effect on bioactivity. The 
Petersson laboratory has recently showed that the single-atom substitution of the 
thioamide can be introduced into protease substrates to stabilize peptides against 
proteolysis. The thioamide modification can be used to stabilize peptides against 
proteolysis in peptide-based medicine while introducing minimal perturbation to the 
structure. 
Thioamide Physical Properties The physical differences between the 
thioamide bond and amide bond are summarized in Table 3. The thioamide bond 
and amide bond are nearly isosteric, but the bond length of the thioamide bond is 
longer. The thioamide bond is weaker and more polarizable compared to the amide 
bond.59 The most significant differences between thioamide and amide are in the 
hydrogen bond donor-acceptor properties. The sulfur atom in the thioamide is a 
weaker hydrogen bond acceptor, but the adjacent N-H group is a stronger 
hydrogen bond donor.60  
 
Table 3. Thioamide Properties 
X=O or S Oxoamide Thioamide 
van der Waals radius (Å) 1.40 1.85 
C=X bond length (Å) 1.24 1.54-1.68 
C=X bond dissociation energy (kcal/mol) 170 130 
N-H pKa 17 11-13 
C-N rotational barrier (kcal/mol) ≈15-19 ≈18-22 
π to π* absorption (nm) 190 270 
Oxidation potential (eV) 3.29 1.21 
 
Source: Adapted from Petersson, E. J.; Goldberg, J. M.; Wissner, R. F. Phys. Chem. 
Chem. Phys. 2014, 16, 6827–6837. 
 
Thioamides as Fluorescence Quenchers Sulfur substitution shifts the amide 
π to π* transition from 190 nm (oxo) to 270 nm (thio), giving it spectral overlap with 
UV wavelength fluorophores that permits Förster resonance energy transfer 
(FRET). In addition, there is a 2.1 eV change in the oxidation potential that makes 
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thioamides able to act as electron donors in photo-induced electron transfer (PET) 
reactions.  These two properties allow the thioamide to be used as a quencher of 
fluorophores including cyanophenylalanine (Cnf), acridonylalanine (Acd), 
fluorescein (Fam), 7-methoxycoumarin (Mcm), tryptophan, and tyrosine.60,61 
These quenching interactions can be used to monitor conformational changes in 
proteins or cleavage by proteases, using doubly labeled peptides.62 The Petersson 
laboratory previously developed a real-time proteolysis assay using fluorescence 
labeled thioamide peptide.61 The probe was designed so that the Mcm 
fluorescence was quenched by the thioamide. After the cleavage of the scissile 
bond by the protease, the fluorescence was turned on and gave an increased 
fluorescence signal that could be analyzed by a plate-reader, as shown in Figure 
19. I used this approach to monitor the protease activity in this study.  
General Proteases Properties Proteases, also referred as peptidases, or 
proteinases are enzymes that catalyze the hydrolysis of peptide bonds. Protease 
signaling pathways are vital to many biological processes and the activity of 
proteases is highly regulated in the body.63 For this reason, many protease 
inhibitors have been developed as therapeutics. Captopril is an angiotensin-
converting enzyme (ACE) protease inhibitor for hypertension treatment;63 Ritonavir 
is a (human immunodeficiency virus) HIV protease inhibitor for (acquired 
immunodeficiency syndrome) AIDS treatment;63 Sivelestat is a neutrophil elastase 
inhibitor for acute respiratory failure treatment.63 
The substrates of protease follow a special nomenclature: residues in the N-
terminal direction from the cleaved bond are designated P1, P2, P3, P4 etc.; the 
residues in C-terminal direction are designated P1', P2', P3', P4'. etc.64 Based on 
the site of cleavage, proteases can be divided in to endopeptidase and 
exopeptidase. Endopeptidase cleave peptide bonds of at non-terminal amino acids 
while exopeptidase cleave peptide bonds of terminal amino acids. Based on the 
mechanism of catalysis, proteases in mammals can be classified into five classes: 
aspartic, cysteine, serine, threonine, and metalloproteases proteases.65 Among 
these classes, serine protease class is the best studied class, which uses the 
classical Ser/His/Asp catalytic triad mechanism, where the serine residue is used 
as the nucleophile.66 Since proteases degrade peptide-based medicine in vivo, it 
is critical to understand the effect of thioamide incorporation with different classes 
of proteases.  
Previous Thiopeptide Protease-Resistant Studies Since hydrogen bonds 
play critical roles in biological activities, the altered hydrogen bond properties can 
change the potency and stability of the peptide. The changes of properties depend 
on the site of incorporation. A thioamide at position 2 of the Leu-enkephalin (Leu-
Enk) peptide increased the potency, but a thioamide at position 1 or 3 decreased 
the potency, as shown in Figure 20.67 Certain thioamide peptides has been shown 
to be resistant against carboxypeptidase A,68–71 HIV-1 proteases,72 membrane 
dipeptidase,73 papain,74 trypsin,75 leucine aminopeptidase,76 and prolyl 
oligopeptidase.77 Some studies have also previously evaluated the effectiveness 
of thio-peptide therapeutics in vivo. Zhang and coworkers78 showed that polybia-
MPI thio-peptides has increased the half-life and anticancer activity. Zacharie and 
coworkers79 reported thioamide Imreg peptides have slightly improved in vivo 
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immune-stimulant effect and serum half-life. In all studies, the activity and 
proteolysis stability of thioamide largely depends on the position of thioamide 
incorporation.  
 
 
Figure 19. Mechanism of Singly Labeled Fluorescence Probe.61  
 
 
Figure 20. Chemical Structure of Leu-enkephalin Peptide.67 
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Purpose For applications in peptide therapeutics, the positioning of the 
thioamide must be disruptive to interactions with the protease, but not with the 
peptide receptor. The Petersson laboratory has demonstrated thioamide peptide 
can stabilize GLP-1 without disrupting activity in cell based assays.80 In separate 
work, the Petersson laboratory has demonstrated that thioamide quenchers can 
be used in fluorescent peptide sensors to probe to protease activity.61 In the case 
of protease sensors, one wishes the thioamide to be as close as possible to the 
scissile bond without altering kcat or KM compared to the parent peptide. To fulfill 
both requirements for thioamide, it is important to gain a predictive understanding 
of which thioamide positions are disruptive for a given protease. To gain a better 
understanding of the positional effects of thioamide, I synthesized a set of probes 
with thioamide at each peptide bond positions and measure the rates of proteolysis. 
Experimental Design The Petersson laboratory previously demonstrated that 
thioamides can be used as fluorescence quenchers in protease activity sensors 
using the probe shown in Figure 19. This sensor can monitor the activity of 
protease, but cannot be used to study the positional effect of thioamide due to 
limitations to the possible positions of thioamide incorporation. The singly labeled 
probe cannot provide kinetic information for the oxo-peptide control. To overcome 
these two problems, a doubly labeled peptide sensor was designed with identical 
fluorophores at each end, as shown in Figure 21 (fluorophores highlighted in blue). 
7-methoxycoumarin (Mcm) was chosen as the fluorophore for the sensor since 
Mcm can be quenched by both thioamide and by intramolecular self-quenching. 
This probe design can monitor the rate of proteolysis with thioamide incorporated 
at any peptide bond position. The synthesis and proteolysis assays followed the 
previous established methods.61 
 
 
Figure 21. Proposed Template of Doubly Labeled Thioamide Proteolysis Sensor 
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Materials and Methods 
 
General Information Fmoc-β-(7-methoxycoumarin-4-yl)-Ala-OH (µ) was 
purchased from Bachem (Torrance, CA, USA). Fmoc-Lys(biotinyl)-OH was 
purchased from TCI America (Portland, OR, USA). 2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), 2-Chlorotrityl chloride 
resin (100-200 mesh, 1% DVB), Fmoc-Ala-OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-
OH were purchased from Novabiochem (currently EMD Millipore; Billerica, MA, 
USA). Piperidine was purchased from American Bioanalytical (Natick, MA, USA). 
Sigmacote®, N,N-diisopropylethylamine (DIPEA), 1,8-Diazabicyclo[5.4.0]undec-
7-ene (DBU) and Trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Glass peptide synthesis reaction vessels (RVs) were treated 
with Sigmacote® prior to use. Triisopropylsilane (TIPS) was purchased from Santa 
Cruz Biotechnology (Dallas, TX, USA). Chymotrypsin (lyophilized powder; from 
Bovine Pancreases) was purchased from MP Biomedicals (Santa Ana, CA, USA). 
Nα-Fmoc-L-Alanine-2-amino-5-nitroanilide and Nα-Fmoc-L- Phenylalanine-2-
amino-5-nitroanilide were synthesized by former lab member Yanxin Wang. All 
other reagents including solvents were purchased from Fisher Scientific (Hampton, 
NH, USA) unless specified otherwise.  
Instruments Crude peptides were purified with a Varian ProStar High-
Performance Liquid Chromatography (HPLC) instrument outfitted with a diode 
array detector (currently Agilent Technologies) using aqueous A (H2O + 0.1% TFA) 
and organic B (CH3CN + 0.1% TFA) phases. Purification testing was performed in 
an Agilent 1100 Series HPLC with a 4.6nm Phenomenex Luna C8 (2) column. UV 
absorbance spectra were obtained with a Hewlett-Packard 8452A diode array 
spectrophotometer (currently Agilent Technologies; Santa Clara, CA, USA). 
Matrix-assisted laser desorption ionization (MALDI) mass spectrometry (MS) data 
were collected with a Bruker Ultraflex III MALDI-TOF-TOF mass spectrometer 
(Billerica, MA, USA). Fluorescence spectra were collected with a Tecan M1000 
plate reader (San Jose, CA, USA) 
Peptide Synthesis The synthesis of thioamide peptide was performed following 
a published method.81 For amino acids other than thioamide-containing amino 
acids, a standard synthetic method identical to Chapter 1 was performed. To 
couple the thioamide, 2 equiv. of pre-activated precursors was dissolved in 2 ml of 
dry dichloromethane (DCM) and then added to the RV. 2 equiv. of DIPEA was 
added to the RV and stirred for 30 min. The RV was drained, then another 2 equiv. 
of pre-activated precursors in dry DCM was added to the RV with 2 equiv. of DIPEA, 
stirred for 30min and then drained. The Fmoc deprotection for thioamide amino 
acids was performed by treatment with 2% 1,8-Diazabicyclo[5.4.0]undec-7-ene 
(DBU) in DMF for 2 min, for three times.  
After the last synthesis step, the peptide was cleaved from the resin by 
treatment of 2 ml of cleavage cocktail for 30 minutes with stirring (30% TFA, 2.5% 
TIPS, 2.5% water, 65% DCM). The TFA from crude peptide was removed by 
adding 2 ml of ACN and evaporated in a rotary evaporator twice. The crude peptide 
was then purified by HPLC and freeze dried. MALDI-TOF was used to confirm the 
identity of the peptide and purity was verified by an analytical HPLC.  
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Steady State Protease Assays To obtain kinetic data of peptide hydrolysis, 
the peptide was dissolved in 100 mM Tris-HCl buffer (pH 7.8) and standardized 
the concentration by measuring the UV absorbance at 325 nm to 5.0 µM. The 
peptides were added to a 96-well plate (Greiner Bio-One, 675096) and incubated 
in the Tecan plate reader with shaking between each measurement at 25 °C. The 
fluorescence was monitored as a function of time using excitation wavelength of 
325 nm and emission wavelength of 390 nm. Chymotrypsin enzyme was dissolved 
in 1 mM HCl, 10mM CaCl2, to a final concentration of 2.5 mg/ ml. The hydrolysis 
was initiated by adding 4 µl of the enzyme to each 46 µl peptide, making a final 
enzyme concentration of 0.2 mg/ml. For control groups, 4 µl of 1 mM HCl, 10mM 
CaCl2 was added to the peptide. Each hydrolysis trail was performed in triplicates 
and control in duplicates. The result of the three trials was averaged and fitted to 
the one phase decay exponential function using GraphPad Prism to calculate the 
half-life. 
 
Results and Discussion 
 
Peptide Characterization To monitor the positional effects of thioamides on 
chymotrypsin proteolysis, doubly Mcm-labeled peptides with a thioamide at each 
peptide position from P4 to P3’ were synthesized (10-16). The corresponding oxo-
peptide was also synthesized as the control (9). Peptide 9, 13-15 were synthesized 
by Chunxiao Liu, Peptide 15 was synthesized by Xing Chen. I synthesized peptide 
10-12. All peptides synthesized were characterized by MALDI-MS, expected 
[M+H]+ ions were observed as shown in Table 4, which μ refers to Mcm derivative 
β-(7-methoxycoumarin-4-yl)-Ala and superscript S refers to position of thioamide. 
 
Table 4. Characterization of Thioamide Peptides 
Molecule Sequence Calculated (m/z) Observed (m/z) 
9 μKAAFAAAμ 1139 1139 
10 μKSAAFAAAμ 1155 1155 
11 μKASAFAAAμ 1155 1155 
12 μKAASFAAAμ 1155 1155 
13 μKAAFSAAAμ 1155 1155 
14 μKAAFASAAμ 1155 1155 
15 μKAAFAASAμ 1155 1155 
16 μKAAFAAASμ 1155 1155 
 
Enzyme Activity Assays Positional screening of thio-peptides hydrolysis from 
P4 to P3’ positions was performed using chymotrypsin. Chymotrypsin hydrolysis 
was carried out with 45 µl of the 5µM peptide concentration in 100 mM HCl, pH 
7.8, at room temperature in the presence or absence of 0.2 mg/ml chymotrypsin. 
Figure 22 shows the fluorescence traces of peptide hydrolysis. The fluorescence 
intensity of peptides without protease (orange traces) was approximately 60% 
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lower than the intensity after hydrolysis (red traces), indicating the doubly labeled 
thioamide peptides was quenched by approximately 60%. The fluorescence 
intensities of peptides without protease (orange traces) remained constant over 
the course of the experiment, demonstrating that the probes were stable during 
the experiment. Upon addition of the protease, the fluorescence signals increased 
exponentially over time and reached plateaus (red traces). This gain of 
fluorescence corresponded to the cleavage of the peptides. For peptides showing 
proteolysis inhibition, the growth of fluorescence intensities was slower and the 
traces were almost linear. The half-lives were calculated by fitting curves to a 
single exponential function using GraphPad Prism, and are shown in Table 5. The 
oxo-peptide 5 could not be fully dissolved in the buffer, hence the hydrolysis 
experiment was not performed. Data for P4 to P1 positions were obtained from 
former lab member Xing Chen.80 The calculated half-lives showed that for 
chymotrypsin, a thioamide at the P1 or P2 position can greatly inhibit proteolysis. 
 
 
 
Figure 22. Representative Results for Chymotrypsin Proteolysis. 
 
Top (left to right): thioamide incorporated to P3, P2, P1 positions, respectively. Bottom 
(left to right): thioamide incorporated to P1’, P2’, P3’ positions, respectively. Red traces: 
Hydrolysis with chymotrypsin; Orange traces: Peptides without chymotrypsin. Three 
independent trials for each protease are shown as open circles, thin lines, and thick lines. 
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Table 5. Thioamide Positional Effects on Chymotrypsin Activity 
Molecule Thioamide 
Position 
Sequence Chymotrypsin t 1/2 (min) 
9 Control μKAAFAAAμ not determined 
10 P4 μKSAAFAAAμ 0.37±0.01 
11 P3 μKASAFAAAμ 1.19±0.02 
12 P2 μKAASFAAAμ >40 
13 P1 μKAAFSAAAμ >40 
14 P1' μKAAFASAAμ 0.19±0.06 
15 P2' μKAAFAASAμ 0.25±0.05 
16 P3' μKAAFAAASμ 0.32±0.06 
 
 
Figure 23. Nucleophilic Attack Step of Serine Protease.83  
Sources: Adapted with permission from Ekici, O. D.; Paetzel, M.; Dalbey, R. E. 
Unconventional Serine Proteases: Variations on the Catalytic Ser/His/Asp Triad 
Configuration. Protein Sci. 2008, 17 (12), 2023–2037. 
 
The protease resistance at the P1 position can be explained by the catalytic 
mechanism. Figure 23 shows the nucleophilic attack step of the serine protease, 
were the serine sidechain serve as a nucleophile and attacks the peptide bond. 
His 57 is pulling a proton from Ser 195 (labeled as 2 in Figure 23 and 24), the 
protonated Ser 195 can act as a nucleophile to attack the amide bond (labeled as 
1). A close examination of the crystal structure of α-chymotrypsin bound with its 
inhibitor shows the P1 position peptide bond is closely interacting with protein 
backbone at Gly 193, Asp 194 and Ser 195 positions, labeled as 3, 4, and 5, 
respectively in Figure 24.82 Since the bond length of thioamide is longer than 
oxoamide and sulfur atom is larger than oxygen, the substrate binding can be 
sterically prohibited and inhibit proteolysis. In addition, the sulfur atom is a weaker 
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hydrogen bond acceptor, the reaction intermediates are destabilized in thioamide 
bonds, making the hydrolysis unfavorable. The inhibition mechanism on the P2 
position is not obvious by inspecting the crystal structure. It is possible that the 
thioamide bond has a higher rotation energy barrier than the amide bond, and the 
substrate with thioamide at the P2 position cannot adapt the correct confirmation.  
For FRET experiment applications, thioamide has the advantage of having a 
smaller size over other FRET quenchers. The typical fluorophores for FRET 
experiments are larger than the size of an amino acid while the thioamide is only 
a single atom substitution. The introduction of a large fluorophore molecule to the 
protein may perturb the structure of the protein and makes the measurements 
unreliable. In contrast, the isosteric thioamide is minimally-perturbing. For peptide-
based medicine applications, thioamides can prevent the drug from protease 
degradation, if incorporated at the right position. However, since the thioamide 
bond is weaker than the oxoamide bond, thioamide peptide drugs may potentially 
have a shorter shelf life.  
 
 
Figure 24. Crystal Structure of Chymotrypsin with Inhibitor from Insect Locusta 
migratoria (PMP-C).82 
 
Sources: Adapted from Roussel, A.; Mathieu, M.; Dobbs, A.; Luu, B.; Cambillau, C.; 
Kellenberger, C. Complexation of Two Proteic Insect Inhibitors to the Active Site of 
Chymotrypsin Suggests Decoupled Roles for Binding and Selectivity. J. Biol. Chem. 2001, 
276 (42), 38893–38898. (PDB ID: 1GL1) 
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Conclusion and Future Work 
 
To evaluate the effect of thioamides to the proteolysis process, collaborators 
and I synthesized one set of hydrolysis sensors with thioamide substitution from 
P4 to P3’ positions, and performed hydrolysis studies using chymotrypsin. The 
result revealed that thioamide at the P1 or P2 positions can greatly inhibit 
chymotrypsin hydrolysis. This initial result of protease inhibition is useful for 
peptide based drug design and other hydrolysis probe design. If peptides of 
therapeutic interest are known to be cleaved by chymotrypsin-like enzymes, they 
could be modified with thioamides at the P2 or P1 positions for stabilization. 
Several future experiments are suggested by our results. Obtaining the 
Michaelis–Menten kinetics parameters of thioamide probes can provide 
information about the mechanism of thioamide proteolysis resistance. Michaelis-
Menten kinetics can be obtained by performing the photolysis experiment at 
different concentrations of the substrates and fit into a Michaelis–Menten model.84 
Enzymatic Thioamide Synthetic Route Although we successfully coupled 
thioamides into peptides, the yields were only approximately 10-25% of the 
corresponding oxo-peptide yield. To make thioamide peptides a more generally-
accessible tool, it is important to optimize the yield of the synthesis. Using an 
enzymatic reaction to introduce a backbone thioamide is a possible way to 
increase yield. Dunbar and Mitchell85 reported an ATP-dependent 
cyclodehydratase that can cyclize a peptide on Cys, Ser, and Thr residues, forming 
a heterocyclic azoline structure (Figure 25). This azoline intermediate can be 
released with KHS, forming a backbone thioamide. This reaction can introduce 
backbone thioamide modifications to an expressed protein at specific locations. 
Currently, such protein can only be made by synthesizing peptide fragments and 
then ligating the fragments. This process is labor intensive and involves multiple 
purification steps. Incorporating thioamide to an expressed protein with enzyme is 
far more efficient.  
 
 
Figure 25. Scheme of Thioamide Formation by Cyclodehyratase.85 
 
Sources: Adapted with permission from Dunbar, K. L.; Mitchell, D. A. Insights into the 
Mechanism of Peptide Cyclodehydrations Achieved through the Chemoenzymatic 
Generation of Amide Derivatives. J. Am. Chem. Soc. 2013, 135 (23), 8692–8701. 
Copyright 2013 American Chemical Society. 
 
  
40 
 
References 
 
1. Brown, J.; Farquhar, C. An Overview of Treatments for Endometriosis. JAMA 
2015, 313 (3), 296–297. 
2. Kumar, P.; Sharma, A. Gonadotropin-Releasing Hormone Analogs: 
Understanding Advantages and Limitations. J. Hum. Reprod. Sci. 2014, 7 
(3), 170–174. 
3. Nguyen, D. P.; Mahesh, M.; Elsässer, S. J.; Hancock, S. M.; Uttamapinant, 
C.; Chin, J. W. Genetic Encoding of Photocaged Cysteine Allows 
Photoactivation of TEV Protease in Live Mammalian Cells. J. Am. Chem. 
Soc. 2014, 136 (6), 2240–2243. 
4. Verdin, E.; Ott, M. 50 Years of Protein Acetylation: From Gene Regulation 
to Epigenetics, Metabolism and Beyond. Nat. Rev. Mol. Cell Biol. 2014, 16 
(4), 258–264. 
5. Liszczak, G.; Goldberg, J. M.; Foyn, H.; Petersson, E. J.; Arnesen, T.; 
Marmorstein, R. Molecular Basis for N-Terminal Acetylation by the 
Heterodimeric NatA Complex. Nat. Struct. Mol. Biol. 2013, 20 (9), 1098–
1105. 
6. Natsume, R.; Eitoku, M.; Akai, Y.; Sano, N.; Horikoshi, M.; Senda, T. 
Structure and Function of the Histone Chaperone CIA/ASF1 Complexed with 
Histones H3 and H4. Nature 2007, 446 (7133), 338–341. 
7. Yang, T.; Li, X.; Bao, X.; Fung, Y. M. E.; Li, X. D. Photo-Lysine Captures 
Proteins That Bind Lysine Post-Translational Modifications. Nat. Chem. Biol. 
2015, 12 (12), 70–72. 
8. Prabakaran, S.; Lippens, G.; Steen, H.; Gunawardena, J. Post-Translational 
Modification: Nature’s Escape from Genetic Imprisonment and the Basis for 
Dynamic Information Encoding. Wiley Interdiscip. Rev. Syst. Biol. Med. 2012, 
4 (6), 565–583. 
9. Brown, Z. Z.; Muller, M. M.; Kong, H. E.; Lewis, P. W.; Muir, T. W. Targeted 
Histone Peptides: Insights into the Spatial Regulation of the 
Methyltransferase PRC2 by Using a Surrogate of Heterotypic Chromatin. 
Angew. Chem., Int. Ed. 2015, 54 (22), 6457–6461. 
10. Arnesen, T. Towards a Functional Understanding of Protein N-Terminal 
Acetylation. PLoS Biol. 2011, 9 (5). 
11. Yu, M.; Gong, J.; Ma, M.; Yang, H.; Lai, J.; Wu, H.; Li, L.; Li, L.; Tan, D. Y. 
Immunohistochemical Analysis of Human Arrest-Defective-1 Expressed in 
Cancers in Vivo. Oncol. Rep. 2009, 21 (4), 909–915. 
12. Yi, C. H.; Pan, H.; Seebacher, J.; Jang, I. H.; Hyberts, S. G.; Heffron, G. J.; 
Vander Heiden, M. G.; Yang, R.; Li, F.; Locasale, J. W.; Sharfi, H.; Zhai, B.; 
Rodriguez-Mias, R.; Luithardt, H.; Cantley, L. C.; Daley, G. Q.; Asara, J. M.; 
Gygi, S. P.; Wagner, G.; Liu, C. F.; Yuan, J. Metabolic Regulation of Protein 
N-Alpha-Acetylation by Bcl-xL Promotes Cell Survival. Cell 2011, 146 (4), 
607–620. 
13. Shemorry, A.; Hwang, C. S.; Varshavsky, A. Control of Protein Quality and 
Stoichiometries by N-Terminal Acetylation and the N-End Rule Pathway. Mol. 
Cell 2013, 50 (4), 540–551. 
41 
 
14. Hwang, C.-S.; Shemorry, A.; Varshavsky, A. N-Terminal Acetylation of 
Cellular Proteins Creates Specific Degradation Signals. Science 2010, 327 
(5968), 973–977. 
15. Zeng, L.; Zhang, Q.; Li, S.; Plotnikov, A. N.; Walsh, M. J.; Zhou, M. 
Mechanism and Regulation of Acetylated Histone Binding by the Tandem 
PHD Finger of DPF3b. Nature 2010, 466 (7303), 258–262. 
16. Taylor, J. P.; Brown, R. H.; Cleveland, D. W. Decoding ALS: From Genes to 
Mechanism. Nature 2016, 539 (7628), 197–206. 
17. Mathis, S.; Couratier, P.; Julian, A.; Corcia, P.; Le Masson, G. Current View 
and Perspectives in Amyotrophic Lateral Sclerosis. Neural Regen. Res. 
2017, 12 (2), 181. 
18. Abe, K.; Itoyama, Y.; Sobue, G.; Tsuji, S.; Aoki, M.; Doyu, M.; Hamada, C.; 
Kondo, K.; Yoneoka, T.; Akimoto, M.; Yoshino, H. Confirmatory Double-Blind, 
Parallel-Group, Placebo-Controlled Study of Efficacy and Safety of 
Edaravone (MCI-186) in Amyotrophic Lateral Sclerosis Patients. Amyotroph. 
Lateral Scler. Front. Degener. 2014, 15 (7–8), 610–617. 
19. Yacila, G.; Sari, Y. Potential Therapeutic Drugs and Methods for the 
Treatment of Amyotrophic Lateral Sclerosis. Curr. Med. Chem. 2014, 21 (31), 
3583–3593. 
20. DeJesus-Hernandez, M.; Mackenzie, I. R.; Boeve, B. F.; Boxer, A. L.; Baker, 
M.; Rutherford, N. J.; Nicholson, A. M.; Finch, N. A.; Flynn, H.; Adamson, J.; 
Kouri, N.; Wojtas, A.; Sengdy, P.; Hsiung, G. Y. R.; Karydas, A.; Seeley, W. 
W.; Josephs, K. A.; Coppola, G.; Geschwind, D. H.; Wszolek, Z. K.; Feldman, 
H.; Knopman, D. S.; Petersen, R. C.; Miller, B. L.; Dickson, D. W.; Boylan, 
K. B.; Graff-Radford, N. R.; Rademakers, R. Expanded GGGGCC 
Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes 
Chromosome 9p-Linked FTD and ALS. Neuron 2011, 72 (2), 245–256. 
21. Mori, K.; Weng, S.-M.; Arzberger, T.; May, S.; Rentzsch, K.; Kremmer, E.; 
Schmid, B.; Kretzschmar, H. A.; Cruts, M.; Van Broeckhoven, C.; Haass, C.; 
Edbauer, D. The C9orf72 GGGGCC Repeat Is Translated into Aggregating 
Dipeptide-Repeat Proteins in FTLD/ALS. Science 2013, 339 (6125), 1335–
1338. 
22. Donnelly, C. J.; Zhang, P. W.; Pham, J. T.; Heusler, A. R.; Mistry, N. A.; 
Vidensky, S.; Daley, E. L.; Poth, E. M.; Hoover, B.; Fines, D. M.; Maragakis, 
N.; Tienari, P. J.; Petrucelli, L.; Traynor, B. J.; Wang, J.; Rigo, F.; Bennett, 
C. F.; Blackshaw, S.; Sattler, R.; Rothstein, J. D. RNA Toxicity from the 
ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention. 
Neuron 2013, 80 (2), 415–428. 
23. Jovičić, A.; Mertens, J.; Boeynaems, S.; Bogaert, E.; Chai, N.; Yamada, S. 
B.; Paul, J. W.; Sun, S.; Herdy, J. R.; Bieri, G.; Kramer, N. J.; Gage, F. H.; 
Van Den Bosch, L.; Robberecht, W.; Gitler, A. D. Modifiers of C9orf72 
Dipeptide Repeat Toxicity Connect Nucleocytoplasmic Transport Defects to 
FTD/ALS. Nat. Neurosci. 2015, 18 (9), 1226–1229. 
24. Shi, K. Y.; Mori, E.; Nizami, Z. F.; Lin, Y.; Kato, M.; Xiang, S.; Wu, L. C.; Ding, 
M.; Yu, Y.; Gall, J. G.; McKnight, S. L. Toxic PRn Poly-Dipeptides Encoded 
by the C9orf72 Repeat Expansion Block Nuclear Import and Export. Proc. 
42 
 
Natl. Acad. Sci. U. S. A. 2017, 114 (7), 1111–1117. 
25. Taylor, J. P. A PR Plug for the Nuclear Pore in Amyotrophic Lateral Sclerosis. 
Proc. Natl. Acad. Sci. 2017, 114 (7), 1445–1447. 
26. Gupta, R.; Lan, M.; Mojsilovic-Petrovic, J.; Choi, W. H.; Safren, N.; Barmada, 
S.; Lee, M. J.; Kalb, R. The Proline/Arginine Dipeptide from Hexanucleotide 
Repeat Expanded C9ORF72 Inhibits the Proteasome. eneuro 2017, 4 (1), 
ENEURO.0249-16.2017. 
27. Calce, E.; De Luca, S. The Cysteine S-Alkylation Reaction as a Synthetic 
Method to Covalently Modify Peptide Sequences. Chem. Eur. J. 2017, 23 
(2), 224–233. 
28. Castro, V.; Rodríguez, H.; Albericio, F. CuAAC: An Efficient Click Chemistry 
Reaction on Solid Phase. ACS Comb. Sci. 2016, 18 (1), 1–14. 
29. Merrifield, R. B. B. Solid Phase Peptide Synthesis. I. The Synthesis of. J. 
AM. CHEM. SOC. 1963, 86 (14), 2149–2154. 
30. Pedersen, S. L.; Tofteng, A. P.; Malik, L.; Jensen, K. J. Microwave Heating 
in Solid-Phase Peptide Synthesis. Chem. Soc. Rev. 2012, 41 (5), 1826–
1844. 
31. Bray, B. L. Large-Scale Manufacture of Peptide Therapeutics by Chemical 
Synthesis. Nat. Rev. Drug Discov. 2003, 2 (7), 587–593. 
32. Hackenberger, C. P. R.; Schwarzer, D. Chemoselective Ligation and 
Modification Strategies for Peptides and Proteins. Angew. Chem., Int. Ed. 
2008, 47 (52), 10030–10074. 
33. Dawson, P. E.; Muir, T. W.; Clark-Lewis, I.; Kent, S. B. Synthesis of Proteins 
by Native Chemical Ligation. Science 1994, 266 (5186), 776–779. 
34. Thapa, P.; Zhang, R. Y.; Menon, V.; Bingham, J. P. Native Chemical Ligation: 
A Boon to Peptide Chemistry. Molecules 2014, 19 (9), 14461–14483. 
35. Zheng, J.-S.; Tang, S.; Qi, Y.-K.; Wang, Z.-P.; Liu, L. Chemical Synthesis of 
Proteins Using Peptide Hydrazides as Thioester Surrogates. Nat. Protoc. 
2013, 8 (12), 2483–2495. 
36. Wan, Q.; Danishefsky, S. J. Free-Radical-Based, Specific Desulfurization of 
Cysteine: A Powerful Advance in the Synthesis of Polypeptides and 
Glycopolypeptides. Angew. Chem., Int. Ed. 2007, 46 (48), 9248–9252. 
37. Saxon, E.; Armstrong, J. I.; Bertozzi, C. R. A “traceless” Staudinger Ligation 
for the Chemoselective Synthesis of Amide Bonds. Org. Lett. 2000, 2 (14), 
2141–2143. 
38. Tam, J. P.; Xu, J.; Eom, K. D. Methods and Strategies of Peptide Ligation. 
Biopolymers - Peptide Science Section. 2001, pp 194–205. 
39. Coin, I.; Beyermann, M.; Bienert, M. Solid-Phase Peptide Synthesis: From 
Standard Procedures to the Synthesis of Difficult Sequences. Nat. Protoc. 
2007, 2 (12), 3247–3256. 
40. Mapelli, C.; Natarajan, S. I.; Meyer, J.-P.; Bastos, M. M.; Bernatowicz, M. S.; 
Lee, V. G.; Pluscec, J.; Riexinger, D. J.; Sieber-McMaster, E. S.; Constantine, 
K. L.; Smith-Monroy, C. a; Golla, R.; Ma, Z.; Longhi, D. a; Shi, D.; Xin, L.; 
Taylor, J. R.; Koplowitz, B.; Chi, C. L.; Khanna, A.; Robinson, G. W.; 
Seethala, R.; Antal-Zimanyi, I. a; Stoffel, R. H.; Han, S.; Whaley, J. M.; 
Huang, C. S.; Krupinski, J.; Ewing, W. R. Eleven Amino Acid Glucagon-like 
43 
 
Peptide-1 Receptor Agonists with Antidiabetic Activity. J. Med. Chem. 2009, 
52 (23), 7788–7799. 
41. Zhang, C.; Dai, P.; Spokoyny, A. M.; Pentelute, B. L. Enzyme-Catalyzed 
Macrocyclization of Long Unprotected Peptides. Org. Lett. 2014, 16 (14), 
3652–3655. 
42. Atanasijevic, T.; Shusteff, M.; Fam, P.; Jasanoff, A. Calcium-Sensitive MRI 
Contrast Agents Based on Superparamagnetic Iron Oxide Nanoparticles 
and Calmodulin. Proc. Natl. Acad. Sci. U. S. A. 2006, 103 (40), 14707–14712. 
43. Behrens, C. R.; Ha, E. H.; Chinn, L. L.; Bowers, S.; Probst, G.; Fitch-Bruhns, 
M.; Monteon, J.; Valdiosera, A.; Bermudez, A.; Liao-Chan, S.; Wong, T.; 
Melnick, J.; Theunissen, J. W.; Flory, M. R.; Houser, D.; Venstrom, K.; 
Levashova, Z.; Sauer, P.; Migone, T. S.; Van Der Horst, E. H.; Halcomb, R. 
L.; Jackson, D. Y. Antibody-Drug Conjugates (ADCs) Derived from 
Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and 
Other Pharmacological Properties over Conventional Heterogeneous ADCs. 
Mol. Pharm. 2015, 12 (11), 3986–3998. 
44. Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. A Stepwise 
Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective 
“Ligation” of Azides and Terminal Alkynes. Angew. Chem., Int. Ed. 2002, 41 
(14), 2596–2599. 
45. Baskin, J. M.; Prescher, J. A.; Laughlin, S. T.; Agard, N. J.; Chang, P. V.; 
Miller, I. A.; Lo, A.; Codelli, J. A.; Bertozzi, C. R. Copper-Free Click Chemistry 
for Dynamic in Vivo Imaging. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (43), 
16793–16797. 
46. Presolski, S. I.; Hong, V. P.; Finn, M. G. Copper-Catalyzed Azide-Alkyne 
Click Chemistry for Bioconjugation. In Current Protocols in Chemical Biology; 
John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2011; Vol. 3, pp 153–162. 
47. Dorman, G.; Prestwich, G. D. Using Photolabile Ligands in Drug Discovery 
and Development. Trends Biotechnol. 2000, 18 (2), 64–77. 
48. Kramer, K.; Sachsenberg, T.; Beckmann, B. M.; Qamar, S.; Boon, K.-L.; 
Hentze, M. W.; Kohlbacher, O.; Urlaub, H. Photo-Cross-Linking and High-
Resolution Mass Spectrometry for Assignment of RNA-Binding Sites in 
RNA-Binding Proteins. Nat. Methods 2014, 11 (10), 1064–1070. 
49. Gomes, A. F.; Gozzo, F. C. Chemical Cross-Linking with a Diazirine 
Photoactivatable Cross-Linker Investigated by MALDI- and ESI-MS/MS. J. 
Mass Spectrom. 2010, 45 (8), 892–899. 
50. Isidro, A.; Latassa, D.; Giraud, M.; Alvarez, M.; Albericio, F. 1,2-
Dimethylindole-3-Sulfonyl (MIS) as Protecting Group for the Side Chain of 
Arginine. Org. Biomol. Chem. 2009, 7 (12), 2565–2569. 
51. Lan, M. The Role of the Proline-Arginine Dipeptide Repeat in Amyotrophic 
Lateral Sclerosis. M.S. Dissertation, University of Pennsylvania, 
Philadelphia, PA, USA, 2017. 
52. Batjargal, S.; Walters, C. R.; Petersson, E. J. Inteins as Traceless 
Purification Tags for Unnatural Amino Acid Proteins. J. Am. Chem. Soc. 
2015, 137 (5), 1734–1737. 
53. Liu, C. C.; Schultz, P. G. Adding New Chemistries to the Genetic Code. Annu. 
44 
 
Rev. Biochem. 2010, 79 (1), 413–444. 
54. Luscombe, N. M.; Laskowski, R. a; Thornton, J. M. Amino Acid-Base 
Interactions: A Three-Dimensional Analysis of Protein-DNA Interactions at 
an Atomic Level. Nucleic Acids Res. 2001, 29 (13), 2860–2874. 
55. Fosgerau, K.; Hoffmann, T. Peptide Therapeutics: Current Status and Future 
Directions. Drug Discov. Today 2015, 20 (1), 122–128. 
56. Hui, H.; Farilla, L.; Merkel, P.; Perfetti, R. The Short Half-Life of Glucagon-
like Peptide-1 in Plasma Does Not Reflect Its Long-Lasting Beneficial Effects. 
Eur. J. Endocrinol. 2002, 146 (6), 863–869. 
57. Weinstock, M. T.; Francis, J. N.; Redman, J. S.; Kay, M. S. Protease-
Resistant Peptide Design-Empowering Nature’s Fragile Warriors against 
HIV. Biopolymers 2012, 98 (5), 431–442. 
58. Xu, P.; Xu, M.; Jiang, L.; Yang, Q.; Luo, Z.; Dauter, Z.; Huang, M.; Andreasen, 
P. A. Design of Specific Serine Protease Inhibitors Based on a Versatile 
Peptide Scaffold: Conversion of a Urokinase Inhibitor to a Plasma Kallikrein 
Inhibitor. J. Med. Chem. 2015, 58 (22), 8868–8876. 
59. Sifferlen, T.; Rueping, M.; Gademann, K.; Jaun, B.; Seebach, D. β-
Thiopeptides: Synthesis, NMR Solution Structure, CD Spectra, and 
Photochemistry. Helv. Chim. Acta 1999, 82 (12), 2067–2093. 
60. Petersson, E. J.; Goldberg, J. M.; Wissner, R. F. On the Use of Thioamides 
as Fluorescence Quenching Probes for Tracking Protein Folding and 
Stability. Phys. Chem. Chem. Phys. 2014, 16, 6827–6837. 
61. Goldberg, J. M.; Chen, X.; Meinhardt, N.; Greenbaum, D. C.; Petersson, E. 
J. Thioamide-Based Fluorescent Protease Sensors. J. Am. Chem. Soc. 
2014, 136 (5), 2086–2093. 
62. Wissner, R. F.; Batjargal, S.; Fadzen, C. M.; Petersson, E. J. Labeling 
Proteins with Fluorophore/Thioamide Förster Resonant Energy Transfer 
Pairs by Combining Unnatural Amino Acid Mutagenesis and Native 
Chemical Ligation. J. Am. Chem. Soc. 2013, 135 (17), 6529–6540. 
63. Turk, B. Targeting Proteases: Successes, Failures and Future Prospects. 
Nat. Rev. Drug Discov. 2006, 5 (9), 785–799. 
64. Harper, E.; Berger, A. On the Size of the Active Site in Proteases: Pronase. 
Biochem. Biophys. Res. Commun. 1972, 46 (5), 1956–1960. 
65. López-Otín, C.; Bond, J. S. Proteases: Multifunctional Enzymes in Life and 
Disease. J. Biol. Chem. 2008, 283 (45), 30433–30437. 
66. Ekici, O. D.; Paetzel, M.; Dalbey, R. E. Unconventional Serine Proteases: 
Variations on the Catalytic Ser/His/Asp Triad Configuration. Protein Sci. 
2008, 17 (12), 2023–2037. 
67. Maziak, L.; Lajoie, G.; Belleau, B. Productive Conformation in the Bound 
State and Hydrolytic Behavior of Thiopeptide Analogs of Angiotensin-
Converting Enzyme Substrates. J. Am. Chem. Soc. 1986, 108 (1), 182–183. 
68. Mock, W. L.; Chen, J. T.; Tsang, J. W. Hydrolysis of a Thiopeptide by 
Cadmium Carboxypeptidase A. Biochem. Biophys. Res. Commun. 1981, 
102 (1), 389–396. 
69. Bond, M. D.; Holmquist, B.; Vallee, B. L. Thioamide Substrate Probes of 
Metal-Substrate Interactions in Carboxypeptidase a Catalysis. J. Inorg. 
45 
 
Biochem. 1986, 28 (2–3), 97–105. 
70. Bartlett, P. a; Spear, K. L.; Jacobsen, N. E. A Thioamide Substrate of 
Carboxypeptidase A. Biochemistry 1982, 21 (7), 1608–1611. 
71. Nashedt, N. T. Carboxypeptidase A Catalyzed Hydrolysis of Thiopeptide and 
Thionester Analogues of Specific Substrates. An Effect on. Society 1982, No. 
22, 5221–5226. 
72. Yao, S.; Zutshi, R.; Chmielewski, J. Endothiopeptide Inhibitors of HIV-1 
Protease. Bioorg. Med. Chem. Lett. 1998, 8 (6), 699–704. 
73. McElroy, J.; Guthrie, D. J.; Hooper, N. M.; Williams, C. H. Gly-(CSNH)-Phe 
Resists Hydrolysis by Membrane Dipeptidase. Biochem. Soc. Trans. 1998, 
26 (1), S31. 
74. Foje, K. L.; Hanzlik, R. P. Peptidyl Thioamides as Substrates and Inhibitors 
of Papain, and as Probes of the Kinetic Significance of the Oxyanion Hole. 
Biochim. Biophys. Acta - Gen. Subj. 1994, 1201 (3), 447–453. 
75. Cho, K. Synthesis of Fluorescent Peptidyl Thioneamides and the Assay of 
Papain in the Presence of Trypsin. Anal. Biochem. 1987, 164 (1), 248–253. 
76. Beattie, R. E.; Elmore, D. T.; Williams, C. H.; Guthrie, D. J. The Behaviour 
of Leucine Aminopeptidase towards Thionopeptides. Biochem. J. 1987, 245 
(1), 285–288. 
77. Schutkowski, M.; Jakob, M.; Landgraf, G.; Born, I.; Neubert, K.; Fischer, G. 
Probing Substrate Backbone Function in Prolyl Oligopeptidase Catalysis. 
Large Positional Effects of Peptide Bond Monothioxylation. Eur. J. Biochem. 
1997, 245, 381–385. 
78. Zhang, W.; Li, J.; Liu, L. W.; Wang, K. R.; Song, J. J.; Yan, J. X.; Li, Z. Y.; 
Zhang, B. Z.; Wang, R. A Novel Analog of Antimicrobial Peptide Polybia-MPI, 
with Thioamide Bond Substitution, Exhibits Increased Therapeutic Efficacy 
against Cancer and Diminished Toxicity in Mice. Peptides 2010, 31 (10), 
1832–1838. 
79. Zacharie, B.; Lagraoui, M.; Dimarco, M.; Penney, C. L.; Gagnon, L. 
Thioamides: Synthesis, Stability, and Immunological Activities of 
Thioanalogues of Imreg. Preparation of New Thioacylating Agents Using 
Fluorobenzimidazolone Derivatives. J. Med. Chem. 1999, 42 (11), 2046–
2052. 
80. Chen, X. Thioamides in Protease Studies: Many Applications for a Single-
Atom Substitution. Ph.D. Dissertation, University of Pennsylvania, 
Philadelphia, PA, USA, 2017. 
81. Mukherjee, S.; Verma, H.; Chatterjee, J. Efficient Site-Specific Incorporation 
of Thioamides into Peptides on a Solid Support. Org. Lett. 2015, 17 (12), 
3150–3153. 
82. Roussel, A.; Mathieu, M.; Dobbs, A.; Luu, B.; Cambillau, C.; Kellenberger, 
C. Complexation of Two Proteic Insect Inhibitors to the Active Site of 
Chymotrypsin Suggests Decoupled Roles for Binding and Selectivity. J. Biol. 
Chem. 2001, 276 (42), 38893–38898. 
83. Ekici, Ö. D.; Paetzel, M.; Dalbey, R. E. Unconventional Serine Proteases: 
Variations on the Catalytic Ser/His/Asp Triad Configuration. Protein Sci. 
2008, 17 (12), 2023–2037. 
46 
 
84. Roskoski, R. Michaelis-Menten Kinetics. In xPharm: The Comprehensive 
Pharmacology Reference; 2011; pp 1–10. 
85. Dunbar, K. L.; Mitchell, D. A. Insights into the Mechanism of Peptide 
Cyclodehydrations Achieved through the Chemoenzymatic Generation of 
Amide Derivatives. J. Am. Chem. Soc. 2013, 135 (23), 8692–8701. 
 
  
47 
 
Appendices 
 
Appendix A. pET His6 Sumo TEVCysPR20 Plasmid Map 
 
 
  
48 
 
 
